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Abstract
Combining anatomical and spectral information
to enhance MRSI resolution and quantification:
Application to Multiple Sclerosis
Multiple sclerosis is a progressive autoimmune disease that affects young adults.
Magnetic resonance (MR) imaging has become an integral part in monitoring
multiple sclerosis disease. Conventional MR imaging sequences such as fluid
attenuated inversion recovery imaging have high spatial resolution, and can
visualise the presence of focal white matter brain lesions in multiple sclerosis
disease. Manual delineation of these lesions on conventional MR images is
time consuming and suffers from intra and inter-rater variability. Among
the advanced MR imaging techniques, MR spectroscopic imaging can offer
complementary information on lesion characterisation compared to conventional
MR images. However, MR spectroscopic images have low spatial resolution.
Therefore, the aim of this thesis is to automatically segment multiple sclerosis
lesions on conventional MR images and use the information from high-resolution
conventional MR images to enhance the resolution of MR spectroscopic images.
Automatic single time point lesion segmentation is performed using T1-
weighted and fluid attenuated inversion recovery MR images where the brain is
segmented into grey matter, white matter, cerebrospinal fluid and lesions using
a probabilistic framework optimised by the expectation-maximisation technique.
Then, a patch-based super-resolution method is used to increase the spatial
resolution of metabolite maps computed from MR spectroscopic imaging. The
patch-based super-resolution method uses high-resolution T1-weighted and fluid
attenuated inversion recovery images together with the brain segmentations to
regularise the super-resolution process. Finally, we extend the single time point
lesion segmentation idea to two time points lesion segmentation. The two time
points lesion segmentation is performed using T1-weighted and fluid attenuated
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inversion recovery MR images of the two time points optimised using a joint
expectation-maximisation algorithm.
Validation of lesion segmentation methods on clinical datasets shows that they
are accurate and consistent in segmenting multiple sclerosis lesions. Moreover,
we study the association of a clinical biomarker – the Expanded Disability
Status Scale score – and a MR imaging biomarker – new and enlarging lesion
volume – and we observe that in majority of the patients, the new and enlarging
lesion volume volume correlates better with Expanded Disability Status Scale
score’s evolution at patient level than at a group level. This study also shows
the applicability of our method on multi-centre datasets without re-tuning
or re-training, which makes it useful for the clinical use. Validation of the
super-resolution method on synthetic and real images shows that our method
preserves tissue contrast and structural information; and matches well with
the trend of acquired high-resolution MR spectroscopic images. We analyse
N-acetyl aspartate and myo-Inositol metabolites concentration in lesions and in
the surrounding white matter. N-acetyl aspartate metabolite concentration in
lesions is found to be lower compared to the surrounding white matter, and an
opposite trend is observed for the myo-Inositol metabolite concentration.
From this research we conclude that the developed multiple sclerosis lesion
segmentation methods, through their robustness and automation, could bring
an added value to the clinical routine evaluation of multiple sclerosis patients.
Also, the patch-based high-resolution MR spectroscopic images, through its
tissue contrast conservation, can offer better lesion characterisation.
Samenvatting
Combinatie van anatomische en spectroscopische
informatie om MRSI resolutie en kwantificering te
verbeteren: Toepassing op Multiple Sclerose
Multiple sclerose is een progressieve auto-immuunziekte die jonge volwassenen
treft. Magnetische resonantie (MR) is een integraal onderdeel bij het toezicht op
multiple sclerose ziekte. Conventionele MRI sequenties hebben een hoge resolutie
en kunnen de aanwezigheid van focale witte stof hersenletsels bij multiple
sclerose ziekte visualiseren. Manuele aflijningen van deze laesies op conventionele
MR beelden is echter tijdrovend en lijdt aan intra- en inter-rater variabiliteit.
Onder de geavanceerde MRI-technieken, kan MR spectroscopische beeldvorming
aanvullende informatie geven over laesie karakterisering in vergelijking met
conventionele MR-beelden. Maar MR spectroscopische beelden hebben een
lage resolutie. Daarom is het doel van dit proefschrift om de segmentatie van
multiple sclerose laesies op conventionele MR-beelden te automatiseren en de
informatie van hoge-resolutie conventionele MR-beelden te gebruiken om de
resolutie van MR spectroscopische beelden te verbeteren.
Automatische enkel tijdstip laesie segmentatie wordt uitgevoerd met behulp van
T1-gewogen en FLAIR MR-beelden waarbij de hersenen worden gesegmenteerd
in grijze stof, witte stof, cerebrospinale vloeistof en laesies met behulp van
een probabilistisch model geoptimaliseerd door de verwachting-maximalisatie
techniek. Vervolgens wordt een patch-gebaseerde superresolutie methode
ontwikkeld die de resolutie van metaboliet beelden, berekend uit MR
spectroscopische beeldvorming, verhogen. De patch-gebaseerde super-resolutie
methode maakt gebruik van hoge resolutie T1-gewogen en FLAIR beelden
samen met de hersensegmentatie om het super-resolutie proces te regulariseren.
Tot slot, wordt de enkel tijdstip laesie segmentatie idee uitgebreid om twee
tijdstippen laesie segmentatie te bekomen. De twee tijdstippen laesie segmentatie
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wordt uitgevoerd op basis van de T1-gewogen en FLAIR MR beelden van de twee
tijdstippen, en het model wordt geoptimaliseerd met behulp van een gekoppeld
verwachting-maximalisatie algoritme.
Validatie van laesie segmentatie methoden op klinische datasets laat zien dat
ze accuraat en consistent zijn in het segmenteren van multiple sclerose laesies.
Bovendien onderzoeken we de associatie van een klinische biomerker - de
Expanded Disability Status Scale score - en een MRI biomerker - volume
van nieuwe en groeiende laesies - en we zien dat in de meerderheid van de
gevallen het volume van nieuw en groeiende letsels beter correleert met de
evolutie van de Expanded Disability Status Scale score op patientniveau dan op
groepsniveau. De studie heeft ook aangetoond dat onze methode toepasbaar is
op datasets van verschillende centra, zonder calibratie. Dit maakt de methode
aantrekkelijk voor klinisch gebruik. Validatie van de super-resolutie methode
van synthetische en echte beelden toont aan dat onze methode weefselcontrast
en structurele informatie behoudt, en past goed bij de trend van hoge-resolutie
MR spectroscopische beelden. We analyseren N-acetyl aspartaat en myo-Inositol
metabolieten concentratie in laesies en in de omliggende witte stof. N-acetyl
aspartaat metaboliet concentratie laesies blijken lager te zijn dan de omringende
witte stof, en een tegengestelde trend wordt waargenomen voor de myo-Inositol
metaboliet concentratie.
Uit dit onderzoek kunnen we concluderen dat de ontwikkelde multiple
sclerose laesie segmentatie methodes, door hun robuustheid en automatisering,
een toegevoegde waarde kan betekenen voor de klinische routine evaluatie
van multiple sclerose-patiënten. De patch-gebaseerde high-resolution MR
spectroscopische beelden, door middel van het behoud weefselcontrast, kunnen
ook bijdragen tot een beter karakterisering van laesies.
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Chapter 1
Introduction
1.1 Multiple Sclerosis
Multiple Sclerosis (MS) is an inflammatory autoimmune disorder that results
in a neuro-degeneration of the central nervous system (CNS). It is a progressive
disease that disseminates in both space and time in the brain and spinal
cord of adults. MS symptoms can vary from patient to patient; however, the
most common symptoms include (1) motor deficits such as: ataxia (lack of
coordination of muscle movements), weakness, tremor (somewhat rhythmic
relaxation and contraction), and spasticity (muscle stiffness), (2) fatigue:
inability to generate force capacity to carry out normal day to day work, (3)
vision problems: temporary vision loss, eye pain, colour blindness, (4) abnormal
sensations: numbness or tingling in different parts of the body such as arms
and legs, (5) sexual problems, (6) bladder problems [75, 184].
Cause and pathological physiology
The exact cause of MS is unknown. However, it is associated with the destruction
of the myelin sheets in the CNS. In order to describe what causes this destruction,
it is important to introduce the biological terminology. Glial cells are the
non-neural cells found in the CNS that mainly consists of: oligodendrocytes,
microglia and astrocyte cells. An oligodendrocyte is a myelinating cell in the
CNS that synthesises the myelin sheet around a neuron that acts as an insulator
and helps a neuron in communicating with the other neurons. A microglial cell
Sections 1.4, 1.5 and 1.6 have been adapted from: Sima D.M., Loeckx D., Smeets D., Jain S., Parizel P.M.,
and Van Hecke W. Use Case I: Imaging Biomarkers in Neurological Disease. Focus on Multiple Sclerosis, In
Imaging Biomarkers: Development and Clinical Integration, Eds. Martí-Bonmatí, L. and Alberich-Bayarri, A., Springer
International Publishing, 2016, 169-180.
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is a cleaning agent that constantly scavenges for dead/damaged neurons and
infectious agents in the CNS. An astrocyte cell provides structural support to
the neurons and helps in neuronal growth and repair. Moreover, it also provides
biochemical support to endothelial cells that consist of vascular cell adhesion
molecule 1 (VCAM-1) and intracellular adhesion molecule 1 (ICAM-1). These
molecules control the permeability of the blood brain barrier (BBB), which
allows only certain types of substances (e.g. monocytes: a type of white blood
cells) to enter the CNS. Figure 1.1-A provides a visual presentation of this
scenario. In case of MS, due to some unknown factor, a monocyte is wrongly
programmed to induce immune reaction to the MS specific antigen - a substance
that causes the immune system to produce antibodies against it. This monocyte
enters the CNS system through BBB, activating the glial cells to react against
the MS specific antigen. Microglial cells together with other immune cells then
attack the oligodendrocyte cells together with the myelin sheets, resulting in
demyelination. Moreover, attack on the astrocyte cell results in an increase in
the permeability of the BBB resulting in more and more monocytes entering
the CNS (see Figure 1.1-B)[128].
Worldwide prevalence and types
According to the 2013 survey of the global MS atlas, 2.3 million people are
affected worldwide. Although MS is present throughout the world, it is more
commonly found in the European countries, Canada and United States of
America (see figure 1.2). In general, MS is twice as common in women than
men, and the patient life expectancy after MS onset is at least 25 years [109]. The
four main clinical forms of MS are relapsing-remitting MS (RRMS), secondary
progressive MS (SPMS), primary progressive MS (PPMS) and progressive
relapsing MS (PRMS). The most general form of MS is RRMS (∼85%) in which
the patient experiences relapses (when symptoms flare up) that may or may
not recover completely. Approximately 80% of the RRMS patients enter the
SPMS phase. Unlike RRMS, SPMS patients experience permanent neurological
disability along with occasional relapses. The remaining 15% of the patients
who do not have RRMS form at the disease onset, have progressive form of MS:
PPMS or PRMS. In PPMS, the patient has progressive early phase neurological
disability and no early phase relapses. In very few rare cases, some patients
have early phase progressive neurological disability with early phase relapses,
which is known as the PRMS form of MS [113].
1.2 Clinical diagnosis and treatment of MS
The initial symptoms of MS disease often overlap with other diseases such
as acute and recurrent disseminated encephalomyelitis, and thus makes its
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Figure 1.1: Normal working of the immune system (A) followed by its alteration in MS
(B). (Figure 1 from [128]; original caption: Main neuroinflammatory mechanisms probed by
MRI. Modifications of the neurovascular unit include alterations of the BBB permeability,
associated with overexpression of adhesion molecules,which induce blood-borne monocytes to
arrest and crawl along the endothelium, crossing it by diapedesis along loosened intercellular
junctions. Machrophage and microglia activation results in increased MPO activity and
lactate accumulation in the interstitium, along with the presence of cellular debris resulting
from cell damage due to oxidative and excitotoxic phenomena. Article [128] is distributed
under the terms of the Creative Commons Attribution 4.0 International License (http:
//creativecommons.org/licenses/by/4.0), by Springer Publications, Ltd.: Clinical and
translational imaging, 6(5):475-489, copyright © 2015.)
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Figure 1.2: Worldwide prevalence of MS. (Figure from [109]; original caption:
PREVALENCE BY COUNTRY (2013). Reprinted with permission from Multiple Sclerosis
International Federation Atlas of MS 2013, www.atlasofms.org, copyright © 2013.)
diagnosis very challenging. The concept of disease dissemination in space
and time is very important in MS diagnosis as it separates MS from other
diseases. According to the revised McDonald criteria for diagnosing MS, if
the patient suffers two clear attacks (relapses; exacerbation) at least 1 month
apart (dissemination in time) with objective clinical evidence (classification of
presenting symptoms and signs as either monofocal or multifocal) of at least
two lesions disseminated in space are sufficient criteria for MS diagnosis solely
based on clinical grounds [119]. Clinical evolution of MS is characterised by
both motor and cognitive degradation [24, 129]. Pathological changes in the
normal appearing white and grey matter are better correlated with progressive
cognitive deficits than with visual, sensory, and motor symptoms [12, 66, 145].
Based on the clinical symptoms, the most common clinical biomarkers that
are used to monitor disease progression include annualised relapse rate and
Expanded Disability Status Scale (EDSS). EDSS score measures the patient
disability on a scale from 0 to 10, with higher scores signifying worse patient
condition [97].
In current clinical practice of MS, the assessments of the extent of brain damage
and drug efficacy are based on visual inspection of MR images by expert
neurologists and neuroradiologists, who evaluate the presence and distribution
of focal white matter lesions. A huge body of research has been devoted to
white matter lesions, since they are considered to be a distinctive feature for
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the disease diagnosis, progression and treatment.
There is no cure for MS as the underlying cause is still unknown. However,
treatments that can favourably affect MS are generally based on immune
modulation or symptomatic improvements. Immune modulation therapy
decreases the activation and proliferation of monocytes into the CNS.
Examples include interferon-beta, fingolimod, glatiramer acetate, teriflunomide,
nataluzimab, alemtuzumab etc. Symptomatic therapy on the other hand does
not change the underlying disease but pacify the different symptoms’ intensity.
Examples include amantadine for fatigue etc [75].
In the past, reducing the number of relapses and its consequences was the
sole aim of the immune modulation therapies. Recent studies have shown that
both relapses and ongoing MRI activity are associated with the disease activity
[44, 13]. As a result, there is a shift in the primary aim of the treatment being
‘no evidence of disease activity’ (NEDA)[69]. NEDA refers to ‘freedom from
the disease activity’. It is a new and evolving concept that aims to monitor
treatment of RRMS patients to reach a state where they have (a) no relapses (b)
no new and active lesions on their MRI scans (c) no increase in their disability.
The revised NEDA criteria [88] also include brain volume change (also known as
brain atrophy) to improve the predictive value of the treatment. The inclusion
of MRI based measures in the NEDA criteria shows the growing importance of
MRI in monitoring the disease activity.
1.3 MRI in the diagnosis and monitoring of MS
White matter lesions (also known as ‘plaques’) are considered to be a hallmark
of the disease and can be visualised with several MRI sequences [149]:
• T1-weighted MR images: chronic stage lesions with axonal destruction
and irreversible damage appear as dark spots (‘black holes’), compared to
the surrounding white matter (WM) tissue intensities (see Figure 1.3).
• Gadolinium-enhanced T1-weighted MR images: ‘active’ lesions taking
up contrast material, and indicating inflammation and breakdown of the
blood-brain-barrier.
• T2-weighted MR images, fluid attenuated inversion recovery (FLAIR) MR
images and proton density (PD) MR images: on these imaging sequences
with a long repetition time (TR), lesions appear as hyper-intense spots
compared to the surrounding brain parenchyma (see Figure 1.3).
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MS diagnosis using MRI
Diagnosing a patient solely on clinical grounds is often very challenging specially
due to the difficulty in classifying the patient symptoms as disease dissemination
in space. Therefore, the revised McDonald criteria also includes the guidelines on
using the MRI if the patient cannot be solely diagnosed on clinical grounds. The
revised McDonald MRI criterion for dissemination in space criteria includes: (a)
at least one T2 lesion in at least 2 out of 4 CNS areas: spinal cord, infratentorial,
periventricular or juxtacortical. Dissemination in time includes: (a) a new T2
and/or gadolinium-enhancing lesion on follow-up scan, irrespective of its timing
with reference to the baseline scan; (b) simultaneous presence of asymptomatic
gadolinium-enhancing and nonenhancing lesions at any time [119].
MS monitoring using MRI
In a clinical scenario, repeated MRI scans are visually inspected to detect and
monitor disease activity [181]. The most commonly used MRI sequences include
Gadolinium-enhanced T1-weighted MR images and T2-weighted/FLAIR MR
images. Presence of Gadolinium-enhanced lesions indicate ongoing disease
activity, since only new lesions (under 6 weeks old) enhance (see Figure 1.4).
New lesions on a follow-up T2-weighted/FLAIR image suggest an inflammatory
reaction that has developed between two MRI scans and provide information
on the disease activity and disease progression [60, 159].
As the correlation between established MRI biomarkers for monitoring the MS
disease activity and clinical outcome measures is low, there is a need to further
investigate other possible MRI biomarkers [117]. Towards this end, several
studies have shown that a high lesion load and the location of MS lesions have a
predictive value for the development of clinical disability [57, 168]. ‘Lesion load’,
is defined as the total volume of lesions in the brain, is one of the most important
biomarkers in MS for monitoring the disease activity. Often, a distinction is
made between T2-lesions (i.e., lesions that appear hyperintense on T2-weighted
or FLAIR images), T1-lesions (i.e., lesions that appear hypointense on T1-
weighted images, the so-called black holes), as well as contrast-enhancing lesions.
In addition to the lesion load, brain volumetry [67], more specifically, total brain
atrophy [13] and, in particular, grey matter (GM) atrophy [65], are currently
considered to be essential biomarkers for monitoring the MS disease activity,
since they are correlated with the speed of disease progression (see Figure 1.5,
table 1.1). Thus, apart from the detection of lesions, quantification of brain
volumes and atrophy rates are increasingly important in the management of
patients with MS. Combined clinical and MRI course of MS is shown in figure
1.6. Moreover, the inclusion of brain atrophy, and new and active lesions in the
NEDA criteria shows the growing importance of MRI in monitoring the disease
activity.
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Figure 1.3: Top, from left to right: T1-weighted, T2-weighted, proton density and FLAIR
images, obtained in an MS patient. Bottom: same images overlaid with expert manual
delineation of MS lesions. (Data from the ‘MS longitudinal lesion segmentation challenge’,
ISBI 2015; training subject 02, time point 01.)
MRI in monitoring and predicting treatment response in MS
Several clinical trials include standard MRI biomarkers (lesion load, active
T2 lesions, contrast-enhancing lesions) as secondary outcome measures while
investigating the clinical efficacy of a treatment in MS. A meta-analysis of
several treatment trials have shown that the effect of treatment on MRI lesions
in a phase 2 trial reliably predicts the effect on clinical relapse activity in a
consecutive phase 3 trial with the same substance [158]. Translation of clinical
trials outcome is often very difficult to apply in clinical routine. Clinical studies
have demonstrated that the appearance of a new T2 lesion or contrast-enhancing
lesion during the first year of a treatment (mostly on interferon-β) correlates
with disability progression [181, 125, 132].
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Figure 1.4: Active lesion (A) appearance in the post-contrast T1-weighted MRI (red arrow),
(B) absence in the pre-contrast T1-weighted MRI obtained in a patient with relapsing-remitting
multiple sclerosis.
Figure 1.5: Brain atrophy in an MS patient: (A) Baseline scan. (B and C) Regular scans
taken at an interval of 4 years. Progressive neurodegeneration can be seen by the enlargement
of the ventricles, which signify brain volume loss over time.
1.4 MRI acquisition requirements
Widespread application of MR imaging biomarkers is hampered by issues such
as: non-standardised imaging protocols, imaging artefacts, lack of normative
data and manual segmentations to quantify values in clinical practice. In
order to mitigate such issues and promote MR imaging in MS clinical practice,
the MAGNIMS Study Group published guidelines for the use of MRI in MS
diagnosis [137], as well as recommendations to improve imaging and analysis of
brain lesion load and atrophy in longitudinal MS studies [179, 163]. The group
recommends that ‘images should be acquired using 3D pulse sequences, with
near-isotropic spatial resolution and multiple image contrasts to allow more
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Figure 1.6: Combined clinical and MRI course of MS. Figure from [58]; original caption:
Typical clinical and MRI course of multiple sclerosis. MRI activity (vertical arrows) indicates
an inflammatory process as measured on brain MRI by gadolinium enhancement or new
T2 hyperintense brain lesion. MRI activity is typically more frequent than clinical relapses
(spikes in clinical disability), which indicates that more disease activity is taking place than
is clinically apparent. Loss of brain volume and increase in disease burden (total volume of
lesions), both measured on MRI, indicate permanent tissue damage, which is present early
in the disease and gradually progresses over time. Reprinted with permission from Fox RJ,
Cohen JA. Multiple sclerosis: the importance of early recognition and treatment. Cleve Clin
J Med 2001; 68:157-171. Copyright © 2001 Cleveland Clinic Foundation. All rights reserved.
Table 1.1: Evidence for the relevance of lesion and atrophy biomarkers in MS.
Biomarker Findings Study population Reference
T2-lesions annualised change: +0.25 ± 0.5 ml 10-year follow-up, RRMS [68]
T1-lesions annualised change: +0.20 ± 0.31 ml Idem Idem
T2-lesions annualised change: +0.80 ml/year 20-year follow-up, RRMS [57]
T2-lesions correlated with disability progression 10-year follow-up [120]
Total brain atrophy correlated with disability progression Idem Idem
Total brain atrophy
CIS = -0.40% ± 0.47%, >1-year follow-up
[40]RRMS = -0.49% ± 0.65%, 963 subjectsSPMS = -0.64% ± 0.68%,
PPMS = -0.56% ± 0.55%
GM atrophy significant differences between 10-year follow-up [81]progressive vs. non-progressive
GM = Grey matter, CIS = Clinically isolated syndrome, RRMS = Relapsing-remitting multiple sclerosis,
SPMS = Secondary progressive multiple sclerosis, PPMS = Primary progressive multiple sclerosis.
10 INTRODUCTION
comprehensive analyses of lesion load and atrophy, across time points. Image
artefacts need special attention given their effects on image analysis results’ [179].
Image artefacts interfering with MRI readings include radio-frequency (RF)
intensity non-uniformity, phase-encode ghosting, signal wrap, and geometric
distortion due to gradient non-uniformity, and B0 inhomogeneity.
Investigators of the Canadian MRI Consensus Group further specify that ‘a
standardised MRI protocol is important during patient follow-up’ [5]. The
recommended brain MRI sequences are: 3D FLAIR (or axial + sagittal FLAIR),
post-gadolinium T1, axial T2 and/or PD, obtained with a minimum MRI field
strength of 1.5T, and a slice thickness: 1 mm for T1 and ≤ 3 mm for FLAIR
with no gap; total head coverage should include the entire brain and brainstem.
MSCare, the (US) Consortium of Multiple Sclerosis Centers [169], proposes a
standardised MRI protocol that they regularly update. The recommendations
include (a) sufficient signal-to-noise ratio and resolution (in-plane resolution
of 1 mm2 with ≤ 3 mm slice thickness, no gap), (b) whole brain coverage, (c)
usage of 3D T2-weighted FLAIR (sagittally acquired) or 3D T2-weighted or
2D diffusion weighted imaging sequences (for complete guidelines, see table 2
in [169]). These requirements are sufficient not only for visual assessment, but
also for automated image analysis software, since most packages performing
MRI-based brain segmentation, atrophy computations or lesion segmentation
work either on single MR images or on a subset of multi-parametric images,
simultaneously taken into account.
1.5 MRI analysis methods
1.5.1 Cross-sectional biomarkers
Brain volume computations
The volume of the whole brain, or volumes of brain structures, can be easily
computed through brain segmentation techniques. Brain segmentation implies
that the whole brain, its constituent tissue types, or individual brain sub-
structures, can be identified based on MRI(s). A typical first step is ‘brain
extraction’ or ‘skull stripping’, a preprocessing step that ensures that only brain
tissue is transmitted to the segmentation pathway. Various brain extraction
methods such as the brain extraction tool (BET) [152], brain surface extractor
(BSE) [144], ROBEX [78], etc., are available. Approaches are diverse, including
morphological, geometrical, image processing and modelling operations (hole
filling, surface modelling, edge detection, intensity thresholding, atlas matching,
deformable models, patch-based labelling, etc.). Moreover, the results of
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individual brain extraction methods can be enhanced by applying hybrid
techniques, thus combining results from several individual methods.
After the first step of brain extraction, the process of brain segmentation
can be started. This is typically based on a probabilistic modelling of voxel
intensities, exploiting the fact that different tissue types have different MR
image characteristics. Recent literature provides an excellent overview of
brain segmentation methods [42]. Well-known and validated examples include
FAST [185], SIENAX [153], FreeSurfer [54]. Gaussian mixture models are
popular; image intensities for each tissue type are modelled as a (sum of)
Gaussian components. This modelling is usually performed using expectation-
maximisation (EM), a well-known iterative parameter estimation algorithm.
Spatial priors, serving as starting values and also as spatial constraints, can be
obtained from appropriate brain atlases available in the literature [131]. The
EM framework can be extended to intrinsically model some of the common
distortions present in MR images, such as spatial inhomogeneity of image
intensities known as bias field. Otherwise, such correction should be performed
in pre-processing, e.g., using methods such as N3 or N4ITK [150, 171]. The
EM results are probabilistic, i.e., each voxel is assigned probability of belonging
to each of the classes of interest (WM, GM, cerebrospinal fluid (CSF), etc.).
These maps can be thresholded to obtain hard segmentations. Volumes in
millilitres for each class can be computed either based on the hard or the fuzzy
segmentation, by simply multiplying the sum of the tissue segmentation over
all voxels by the voxel volume.
Lesion detection and volume estimation
Some automatic lesion segmentation methods belong to the family of supervised
classification methods, for which a representative training dataset, including
expert segmentation, is required in order to build a model that can be used
on new patients for lesion segmentation. Depending on the features extracted
from images (local gradient intensity, mean intensity, spatial information, etc.)
and on the type of classifier (k-nearest neighbours, artificial neural networks,
Bayesian learning, support vector machines, etc.), many variants have been
proposed [63, 96, 91, 160]; see also [61, 108] for overviews of algorithms and
software solutions). Although excellent results can be obtained with supervised
classification on the training dataset, these methods have two disadvantages.
The first difficulty lies in building a training dataset that encompasses MS
lesions of all possible shapes, intensities and are heterogeneously distributed in
the WM. The second non-trivial problem lies in pre-processing a new image
(acquired on a different scanner than the one used for the training dataset), such
that it matches the characteristics of the training dataset, e.g., by intensity
normalisation. In other words, supervised methods perform well only when the
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new image to be segmented is well represented in the training dataset.
Another family of methods is based on unsupervised classification and does
not require training images. These methods are usually based on stochastic
modelling of voxel intensity distribution. They perform brain segmentation
into GM, WM and CSF (with or without lesion detection) and often rely on
post-processing approaches in order to segment lesions (e.g., lesion growing or
pruning). The assumptions that are made in order to segment lesions have a
great impact on the results. For instance, Van Leemput et al. [176] use three
MR sequences (T1-, T2- and PD-weighted) to segment MS lesion as an outlier
to the normal brain. In addition, it corrects for MR field inhomogeneities and
incorporates spatial consistency using Markov Random Field. LST [142] detects
FLAIR-hyper-intense outliers, which are further promoted as lesions according
to their spatial probability of being in the WM, where the WM segmentation
is basically derived from T1-weighted image segmentation. Lesion-TOADS
[146], on the other hand, employs a sophisticated mechanism of combining
information from different MR sequences (T1-weighted, T2, PD or FLAIR) in
order to simultaneously segment lesions and brain structures, while distance
maps from the boundaries of structures such as CSF are used to confine the
segmented lesions to typical locations.
1.5.2 Longitudinal biomarkers
In contrast to cross-sectional approaches, longitudinal methods take into account
two (or more) MRI scans of the same subject from different time points
to calculate brain volume changes or atrophy. Typical preprocessing steps
prior to longitudinal atrophy computations include [46]: extraction of the
intracranial cavity mask at baseline; correction of intensity inhomogeneities;
rigid registration of follow-up scans on the baseline scan; and differential bias
field correction to correct for differences in intensity inhomogeneity artefacts.
Longitudinal methods for brain atrophy typically try to match two MRI scans
using registration techniques and directly extract small changes in brain volume
from this process. Approaches include brain edge motion analysis, voxel-
based statistical analysis for voxel-based morphometry, statistical parametric
mapping, and local Jacobian determinant analysis after nonlinear matching
between coregistered images [153, 59, 21, 151].
In what concerns lesions, many methods focus on segmenting MS lesions at a
single time point, and there is not yet a single approach, according to the review
of [101], that can emerge as a standard in clinical practice for the analysis of
lesion evolution over time.
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Although many studies have supported the correlation between the MRI-derived
biomarkers and the clinical biomarkers (especially EDSS), this correlation is
not very strong. This could be explained by the functional and structural
redundancies in the brain that prevent this damage to be measured by clinical
measurements such as EDSS. Thus MRI-derived biomarkers seem to be more
sensitive than clinical biomarkers [58, 136]. Because of the low correlation,
MRI-derived biomarkers are not yet standardised and still under development
[77, 32, 60, 5].
1.6 Advanced MRI sequences for MS
In spite of the high sensitivity of conventional MRI derived metrics for detecting
MS lesions in the white matter, they still have several limitations such as:
(a) detecting the actual spatial extent of a lesion, (b) lesion characterisation
(remyelinating, demyelinating, edema, necrosis etc.), (c) understanding the
disease pathogenesis etc. Advanced techniques, such as diffusion tensor imaging
(DTI), magnetisation transfer imaging, proton MR spectroscopy (MRS), can
address these issues and may therefore help in reducing the gap between the MRI
and clinical findings. We now explain the principle of each of these techniques
together with their use in MS research.
Diffusion tensor imaging
Diffusion tensor imaging (DTI) measures the diffusivity of water molecules inside
the tissue. This phenomenon happens at the microscopic level, well beyond
the conventional MRI resolution. The two commonly used DTI measures in
MS are fractional anisotropy (FA) and mean diffusivity (MD). FA measures
the directional diffusivity and MD measures the overall diffusion magnitude. In
case of MS, myelin sheet damage around fibres results in a decreased anisotropy
of diffusion [183] and is associated with the diffuse injury and rupture of the
tissue architecture [136]. This results in an increased MD and decreased FA in
the normal appearing brain tissue.
Magnetisation transfer imaging
Magnetisation transfer imaging measures the transfer of magnetisation between
the free mobile protons in the water pool and the protons that are attached to
macromolecules. As the myelin sheet contributes to these macromolecules, the
destruction of myelin sheets can also be quantified using this technique [143].
By applying the MR sequences with and without an off resonance saturation
pulse, magnetisation transfer ratio (MTR) can be computed. In MS, a decrease
in MTR value is associated with the demyelination [49].
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Figure 1.7: (a) Bias corrected FLAIR image followed by (b) overlaid lesion segmentation
from an automated method, and (c) the acquired myo-Ins map. The myo-Ins concentration
increases from red to blue. The MRSI map of the myo-Ins shows more extent of pathological
changes in white matte compared to the conventional FLAIR MRI [111, 166].
Proton magnetic resonance spectroscopy
1H-MRS provides information on the chemical composition of the underlying
tissue. This chemical information is assessed by quantifying cellular metabolites
such as N-acetyl Aspartate, choline, myo-inositol etc. Every metabolite has a
function and its increase or decrease gives an indication about the health of
the underlying tissue such as the state of the myelin sheets in case of MS. As
chemical changes are very sensitive to the underlying pathology compared to
conventional MR sequences [111, 166], MRS can play a very important role in
understanding pathophysiology, diagnosis of disease in its very early stage and
characterisation of lesions (see Figure 1.7). We describe MRS more in detail in
the following section.
1.7 Magnetic resonance spectroscopy (MRS)
1.7.1 Metabolites in MS
In MS, the most frequently quantified metabolites are N-acetyl Aspartate
(NAA), myo-inositol (myo-Ins), glutamate and glutamine (Glx), choline (Cho)
and creatine (Cr). NAA is produced in the mitochondria (power house) of
neurons thus it is a marker for neuronal health. In the early phase of MS,
the NAA concentration increases and decreases representing the remyelination
and demyelination, and as the disease progresses its concentration decreases.
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Table 1.2: Evidence for the relevance of NAA metabolite in MS.
Region Findings Study population Reference
Lesion Reduced concentration w.r.t. controls
RRMS (n=9),
[37]SPMS (n=10),PPMS (n=6),
Controls (n=9)
NAWM Initial increase followed 2 year early follow-up of 20 RRMS [167]by partial recovery patients and 10 controls
NAWM (corpus callosum) Reduced concentration w.r.t. controls 11 RRMS patients and 9 controls [79]
NAWM Reduced concentration w.r.t. controls
RRMS (n=13),
[164]PPMS (n=15),
Controls (n=20)
CGM
Reduced concentration in SPMS RRMS (n=15),
[140]w.r.t. RRMS and controls SPMS (n=15),Controls (n=8)
DGM (thalami) Reduced concentration w.r.t. controls 14 RRMS patients and 14 controls [29, 6]
Whole brain NAA decreased 3.6 faster than atrophy 42 RRMS patients [62]
NAWM = normal appearing white matter, CGM = cortical grey matter, DGM = deep grey matter,
RRMS = Relapsing-remitting multiple sclerosis, SPMS = Secondary progressive multiple sclerosis,
PPMS = Primary progressive multiple sclerosis.
myo-Ins is a specific marker of astrocytes [141] and its increase in MS indicates
the increase in astrocytes that are produced to support and repair neurons.
Glx is the sum of two metabolites: glutamate and glutamine, as their separate
quantification is not easy. Glx is a marker of increased glutamate-mediated
excitotoxicity or increased glutamine concentration. Glutamate-mediated
excitotoxicity is the pathological process in which the neurons are killed due
to excessive activation by neurotransmitters such as glutamate. In a normal
process, glutamate is converted into glutamine by astrocytes and then back
to glutamate by the neuron. In MS, as the neurons die, glutamate synthesis
is diminished, and thus, the glutamine concentration increases as the disease
progresses. Cho consists of contributions from the tri-methylamine groups of
glycerophosphocholine, phosphocholine, and a small amount of free choline
itself [9]. Cho is found in all cell membranes and is associated with changes
in membrane composition, such as membrane turnover and demyelination [70].
Cr signal represents the added contribution of creatine and phosphocreatine
[141]. Cr is associated with cell metabolism and its elevation is attributed to
combined effects of astrocytic demyelination in lesions and oligodendrocytic
remyelination. Both Cho and Cr are found in neurons and glial cells, and were
shown to be much higher in oligodendrocytes and astrocytes of cell culture
extracts. Excess of both cell types probably results in the rise of Cho and Cr
in the MS patients [79]. NAA is the most common metabolite studied in MS
because it is a neuronal marker and the evidence for its relevance in MS is
summarised in table 1.2.
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Figure 1.8: Human brain MR spectrum acquired in vivo at 1.5T showing different metabolites
at their respective resonant frequencies. Echo time = 23 ms, repetition time = 6 sec, 64
averages, single voxel spectroscopy with PRESS sequence.
1.7.2 MRS acquisition
Figure 1.8 shows the healthy human brain 1H-MR spectrum where the resonant
frequencies of different metabolites are expressed in parts per million (ppm),
and is read from right to left. NAA resonates at a frequency of 2 ppm, followed
by Glx between 2.0 – 2.4 ppm, Cr with two peaks at 3.0 ppm and 3.9 ppm,
Cho at 3.2 ppm and myo-Ins at 3.5 ppm. The y-axis of the spectrum represents
the signal intensity, which is expressed in an arbitrary unit due to absence of a
reference signal. A metabolite’s concentration is related to the area under its
MRS signal.
MRS spectra can be acquired using single voxel spectroscopy (SVS) or multi
voxel magnetic resonance spectroscopic imaging (MRSI). In SVS, the single
spectrum of a particular volume can be acquired by first suppressing the water
signal followed by selecting the volume of interest using gradient pulses and
finally acquiring the spectrum using e.g., point-resolved spectroscopy (PRESS)
or stimulated echo acquisition mode (STEAM) sequences [15]. In MRSI, a
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large volume is divided into multiple smaller voxels such that the spectra of
every voxel can be acquired simultaneously. SVS acquisition has advantages
such as higher signal to noise ratio (SNR) and better spectral quality that
are counter balanced by the loss of spatial information and large voxel sizes
in comparison with MRSI [139]. Both acquisition methods can be acquired
at long and short echo times. Long echo time (range: 135-144 ms) results in
detection of limited metabolites (e.g., NAA, Cr and Cho) that have higher
concentration, long T2 relaxation time and uncoupled spin systems. In case
of resonance from strongly coupled spins, the signal decreases rapidly with
echo time due to destructive interactions between resonances with J-coupled
induced phase modulation (internal indirect interaction of two spins via the
intervening electron structure of the molecule). In addition to these long echo
time metabolites, short echo time (range: 20-40 ms) allows the detection of
other metabolites such as myo-Ins, Glx [174].
1.7.3 Metabolite quantification
Preprocessing
Some common pre-processing steps include (a) multiplication with a filter (e.g.
Lorentzian filter in SVS or Hamming filter in MRSI) in the time domain to
improve the signal-to-noise ratio, (b) zero-filling for artificially improving the
spectral resolution, (c) baseline correction with the aim of proper quantification
of small metabolites, and (d) phasing for obtaining a pure absorption mode MR
spectrum [175].
Quantification
The acquired MRSI data, after Fourier transformation from k-space to the
spatial domain, can be fitted in a voxel-by-voxel fashion using a simulated
metabolite basis set, matching the acquisition parameters (e.g., echo time) of
the given signals. The fitting can be based on time-domain MRSI signals, or
after Fourier transformation to the frequency domain. The most widely used
quantification software is LCModel that linearly fits the frequency domain
data to a reference model using a metabolite database [126]. Another popular
software package is jMRUI (Java-based magnetic resonance user interface) where
the data is fitted in the time domain using prior knowledge on coupling patterns,
linewidth etc [112]. Both software packages provide error estimation in data
fitting using Cramer-Rao lower bound [35]. For MRSI, the output consists of
a set of metabolite images (‘metabolite maps’) in arbitrary units, as many as
metabolites in the basis set, and having the same spatial resolution as the input
MRSI grid [174].
In MRSI, absolute quantification is difficult w.r.t. single voxel spectroscopy as
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obtaining the additional reference scan (water signal) is time consuming. The use
of water signal as a reference scan helps in reducing several sources of errors such
as differences in receiver gains etc. [16]. Moreover, chemical shift displacement
error (spatial displacement of off-resonance signal w.r.t. resonance frequency)
is more profound in MRSI due to simultaneous RF slice selection pulses that
result in a spatial displacement of the resonances within the excitation volume.
In many studies, metabolites are measured relative to the Cr concentration,
which is considered to be relatively constant in many diseases including MS.
However, in some studies it has been shown that the Cr level may vary, thus,
providing an error in measurements. Therefore, absolute quantification should
be envisaged [87].
1.7.4 Problems with MRS imaging
Despite the fact that MRSI provides attractive complementary information with
respect to conventional MRI, it is still not widely used in practice. Possible
reasons include (a) low signal to noise ratio, (b) poor spatial resolution, (c)
prolonged acquisition time, (d) lack of standardised protocols, (e) and limited
quality control. Since the metabolite concentrations are very low, a large voxel
size is required in order to capture sufficient signal, resulting in a poor spatial
resolution (typically around 1 cm3). Additionally, this results in a broad point
spread function, which further causes spectral signal leakage in the neighbouring
voxels. This limits the ability to differentiate among spatial features of interest,
e.g., between different tissue types. High spatial resolution MRSI cannot be
acquired in the clinical routine with standard acquisition sequences, as it requires
a long scanning time, e.g., in the range of tens of minutes. Therefore, there is a
need to design alternative, non-conventional approaches to create high-resolution
MRSI-based metabolic images within a limited acquisition time.
1.8 Objectives and main contributions
The main objective of this thesis was to develop an automated method for
combining the information from a low-resolution MRSI scan with a high-
resolution MRI scan with the goal of up-sampling the spectroscopic image.
Using these high-resolution or super-resolution images, this thesis aimed to
better characterise small MS lesions. To this end, several data processing
steps were designed and optimised: lesion segmentation in MRI, matching the
image resolutions between the different modalities, multi-modal data fusion and
metabolite quantification.
OBJECTIVES AND MAIN CONTRIBUTIONS 19
We now list our main contributions along with the associated publications on
MS lesion segmentation and MRSI resolution enhancement:
• An automatic single time point MS lesion segmentation method that
fragments the MR image of an MS brain into GM, WM, CSF and lesions.
The method takes as input 3D T1-weighted and 3D FLAIR MR images
and is optimised using an expectation-maximisation algorithm (chapter
2). We show good accuracy and reproducibility of our method on two
clinical datasets [86, 25].
• A patch-based super-resolution method to increase the spatial resolution
of a low resolution MRSI scan. The method uses high-resolution 3D T1-
weighted and 3D FLAIR MR images together with brain segmentations
to regularise the super-resolution process (chapter 3). Validation on
synthetic and real images shows that our method preserves tissue contrast
and structural information; and matches well with the trend of acquired
high-resolution MRSI [85, 84].
• Two time points white matter lesion segmentation method, that jointly
segments MS lesions of two time points. The method takes as input
(a) 3D T1-weighted and 3D FLAIR MR images of the two time points,
(b) FLAIR based subtraction image, and (c) single time point lesion
segmentations of the two time points; and is optimised using a joint
expectation-maximisation algorithm (chapter 4). Validation on two
clinical datasets shows that our method is both accurate and consistent
in segmenting MS lesions [83].
• A multi-center study on the clinical relevance of the new and the enlarging
lesion volume (computed from the two time points lesion segmentation
method) in RRMS (chapter 5). We observe that in majority of the patients
the new and enlarging lesion volume correlates better with the clinical
biomarker, EDSS score, at patient level than at a group level.
This manuscript is structured as follows.
• We first present the single time point MS lesion segmentation method
in chapter 2 that forms the basis for the super-resolution and two time
points lesion segmentation methods.
• Using the brain segmentation information, patch-based super-resolution
of MRSI is presented in chapter 3.
• Chapter 4 presents the two time points lesion segmentation method, which
takes as input single time point lesion segmentation information of the
two time points.
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Figure 1.9: The graphical representation of the thesis. NEL = new and enlarging lesions.
• New and enlarging lesions (NEL) volume, which is computed using the
two time points lesion segmentation method, is investigated in chapter 5
for its association with the EDSS score.
• Finally, we draw the conclusions and formulate some future perspectives
(chapter 6).
The structure of this thesis is presented in figure 1.9.
Chapter 2
Single time point MS lesion
segmentation
Abstract
The location and extent of white matter lesions on MRI are important criteria
for diagnosis, follow-up and prognosis of MS. Clinical trials have shown that
quantitative values, such as lesion volumes, are meaningful in MS prognosis. In
this chapter, we present MSmetrix-cross, an accurate and reliable automatic
method for lesion segmentation based on MRI. In MSmetrix-cross, 3D T1-
weighted and FLAIR MR images are used in a probabilistic model to detect
WM lesions as an outlier to normal brain while segmenting the brain tissue into
GM, WM and CSF. The actual lesion segmentation is performed based on prior
knowledge about the location (within WM) and the appearance (hyperintense
on FLAIR) of lesions. We show good accuracy and reproducibility of our method
in two clinical datasets which compares favourably with other publicly available
MS lesion segmentation algorithms.
2.1 Introduction
The location and extent of white matter lesions on MRI are important criteria
for diagnosis, follow-up and prognosis of MS. Clinical trials have shown that
The work presented in this chapter has been published in: Jain, S., Sima, D. M., Ribbens, A., Cambron, M.,
Maertens, A., Van Hecke, W., De Mey, J., Barkhof, F., Steenwijk, M. D., Daams, M., et al. Automatic segmentation
and volumetry of multiple sclerosis brain lesions from MR images. NeuroImage: Clinical 8 (2015), 367–375.
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lesion volumes are meaningful outcomes for disease prognosis [170]. Accurately
measuring lesion volumes is, therefore, of considerable interest in clinical practice.
Manual segmentation of MS lesions is time consuming and suffers from large
intra- and inter-observer variability. Therefore, in clinical trials and research
studies, semi-automated methods are increasingly used. The ultimate aim,
however, is to use a fully automated lesion segmentation approach, as it can
further decrease the observer dependency as well as the time needed from the
expert. This will be especially important for large clinical trials, as a huge
amount of data needs processing. For clinical practice, an automated method
would make it possible to measure lesion volumes, thereby further standardising
and quantifying the MRI reading.
In this chapter, MSmetrix-cross is introduced, a robust automatic method
for WM lesion segmentation based on 3D T1-weighted and 3D FLAIR MR
images. The method is independent of scanner and acquisition protocol and
does not require a training image database of expert lesion segmentations. The
proposed method models the WM lesions as an outlier class while classifying
the brain into three classes, GM, WM and CSF using a healthy brain atlas.
The aim of this work is to validate the proposed lesion segmentation method on
two distinct datasets from two clinical centres, used to assess accuracy as well
as reproducibility. In addition, results are compared both quantitatively and
qualitatively with two well-known and publicly available automatic unsupervised
lesion segmentation software implementations: LST [142] and Lesion-TOADS
[146].
2.2 Methods
This section provides more details on the proposed lesion segmentation method
and summarises the publicly available lesion segmentation methods we compare
to. Furthermore, the data and the validation tests used for evaluation of the
methods are described.
2.2.1 Method description
Figure 2.1 shows a schematic overview of the proposed method, which takes as
inputs 3D T1-weighted and a 3D FLAIR image acquired from an MS patient.
The images are preprocessed and co-registered before executing the main loop
of the algorithm, consisting of brain tissue segmentation, lesion segmentation
and lesion filling. We describe each of the steps into more detail below.
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Figure 2.1: Schematic representation of the MSmetrix-cross method.
The first step, the preprocessing, has three stages:
• In the first stage, the input FLAIR image of the patient is rigidly co-
registered with the input T1-weighted image using the normalised cross
correlation coefficient as a similarity measure.
• In the second stage, the T1-weighted input image is skull stripped
classifying each voxel either as a brain region or a non-brain region
based on the affine registration of a brain mask available from the MNI-
atlas using the normalised cross correlation coefficient as a similarity
measure followed by a non-rigid registration using the normalised mutual
information as a similarity measure.
• In the third stage, the probabilistic anatomical priors for GM, WM and
CSF, which are also available from the MNI-atlas, are transferred to the
skull stripped T1-weighted image space using the affine transformation
and non-rigid deformation computed above.
In these preprocessing stages, the rigid and affine registrations use a multi-
resolution approach with a Trimmed Least Square scheme and block-matching
(NiftyReg1, [116]). The non-rigid registration is based on the Free-Form B-spline
deformation model and also uses a multi-resolution approach (NiftyReg, [107]).
In the second step, which builds further on the work of [177], a probabilistic
model is formulated to segment the skull stripped T1-weighted image based on
prior knowledge given by the probabilistic tissue priors mentioned above. The
model assumes a Gaussian distribution of the image intensities per tissue class,
a smoothly varying bias field for the intensity non-uniformities and contains
1http://cmictig.cs.ucl.ac.uk/wiki/index.php/NiftyReg
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a spatial consistency model based on a Markov Random Field (MRF). This
model is optimised using an EM algorithm [177] as implemented in NiftySeg2,
[26]. The algorithm iteratively estimates the parameters of each tissue class, as
well as the bias field parameters, and maintains the spatial consistency until
convergence. After the convergence of the EM algorithm, the T1-weighted image
is bias field corrected and segmented into the three tissue classes, i.e., GM, WM
and CSF.
In the third step, an outlier class is estimated from the co-registered FLAIR
image of the same patient using the three tissue class segmentations from
the previous step as prior information. This is performed using the same
EM algorithm as described in the second step, but now an outlier map is
included [176]. Using the tissue segmentations of the T1-weighted image as
prior information, the intensities of each tissue class in the FLAIR image are
modelled as a normal distribution and the deviation of each FLAIR voxel from
this model is estimated as an outlier belief map. This map is iteratively updated
by the EM algorithm and, after convergence, the FLAIR image is bias field
corrected and an outlier belief image is produced. This outlier belief image is
used as an initialisation for the MS lesion segmentation in the next step.
In the fourth step, we segment the lesions in the outlier map, i.e., we ‘prune’ the
outlier map, as not every outlier is a lesion (e.g., the outlier map might include
partial volume effects, artefacts, etc.). In order to differentiate the MS lesions
from such non-lesion outliers, some extra a priori information about the location
and the appearance of the lesions needs to be incorporated. The outliers need to
be in the WM region, where the WM segmentation is derived from T1-weighted
image segmentation in the second step. Moreover, the underlying intensities
of the outliers should be hyperintense compared to the GM intensities on bias
field corrected FLAIR image. The hyperintensity is defined as a threshold that
is equal to the mean plus two times the standard deviation of GM intensities in
the bias field corrected FLAIR image. Furthermore, another mask based on
co-registered T1-weighted image atlas, is used to exclude areas (WM in-between
the ventricles and in the cortical regions near the great longitudinal fissure)
that are prone to show false lesion segmentation. Finally, each masked outlier
voxel needs to have a minimum number of 5 adjacent outlier voxels (empirically
determined), in order to avoid spurious lesion detection.
In the fifth step, this lesion segmentation is then used to fill in the lesions in the
bias corrected T1-weighted image with WM intensities. This global lesion filling
method is very similar to the LEAP method [28] where the mean and standard
deviation of WM intensities are computed using the WM segmentation from
the second step. In our case, the WM segmentation is a soft segmentation and
2http://niftyseg.sourceforge.net/index.html
METHODS 25
therefore, is thresholded to values above 0.5, in order to make sure that only
WM intensities are included in the statistics. Finally, the whole filled-in volume
is smoothed with a Gaussian kernel of radius 1 voxel, and normalisation is
applied in order to restore the global standard deviation of the WM intensities
as in [28].
Steps 2-5 are repeated until there is no significant change in the tissue and
the lesion segmentation. The idea of repeating the second and the third step
is that the lesions are primarily WM, therefore, the T1-weighted lesion filling
will result in better brain tissues segmentation, which in turn results in better
segmentation of lesions due to the improved WM mask used in the fourth step.
After the last iteration lesions are recovered from the GM segmentation in case
the outlier belief is high. This is because some WM lesions that are very close
to cortical GM might be wrongly segmented as GM and therefore, are missed in
the pruning step, i.e., the fourth step. These lesions are added to the previously
found lesions in the fourth step. Subsequently the T1-weighted image is filled
one more time and segmented again providing the final segmentations of WM,
GM and CSF.
2.2.2 Comparison with state-of-the-art methods
For comparison, the validation tests performed for MSmetrix-cross3 were
executed on the same datasets using two state-of-the-art software packages:
LST and Lesion-TOADS. Unless otherwise stated, default parameter settings
were used for all implementations, thus parameter tuning was not performed
neither at dataset level, nor at patient level.
LST
LST (Lesion Segmentation Tool) v1.2.3 is implemented in SPM84 and is based
on a lesion growth algorithm described in [142] . In short, LST determines GM,
WM and CSF segmentations from T1-weighted images and computes the FLAIR
intensity distributions of these tissue classes. The amount of ‘hyperintensity’ of
each voxel in terms of distance from the mean intensity of the WM, GM and
CSF distributions in the FLAIR image is crucial for defining a conservative
lesion belief map (obtained by thresholding the GM belief map) and a liberal
lesion belief map (consisting of the sum of the three lesion belief maps). Lesion
3MSmetrix-cross pipeline presented here is the version 1.2 of the clinical product –
MSmetrix.
4http://www.fil.ion.ucl.ac.uk/spm/software/spm8/
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growing is then performed iteratively between the conservative and the liberal
belief maps, until no more voxels are added to the lesions.
Lesion-TOADS
Lesion-TOADS [146] is available as a plug-in for the MIPAV software5. Lesion-
TOADS implements an iterative algorithm for fuzzy classification of the image
intensities, using a combination of topological and statistical atlases. An
additional lesion class is added to the brain segmentation model, using the same
spatial prior as WM; lesions and WM are then separated by selecting, inside the
grouped region, whichever has the higher membership value. Prior knowledge
about areas where false positives commonly occur is used to define penalty
weights based on the distance to these areas (e.g., distance to ventricles, GM
structures and interventricular WM). This method segments multichannel input
images simultaneously, using an intensity-weighting scheme that optimises the
effect of each channel onto the segmentation of each tissue class. Although it is
not a default setting, the method is also able to estimate bias field corrections
to deal with local intensity non-uniformities. For a fair comparison against
MSmetrix-cross and LST, where bias field corrections are included by default,
this option was also turned on for Lesion-TOADS, since otherwise its results
were not competitive.
2.2.3 Data
Dataset 1
20 MS patients participated in a study at VU University Medical Center,
Amsterdam, the Netherlands. The study was approved by the local ethics
committee and all patients signed informed consent forms. MR imaging was
performed on a 3T whole body scanner (GE Signa HDxt, Milwaukee, WI, USA).
The protocol contained two 3D sequences: a fat-saturated 3D FLAIR (TR:
8000 ms, TE: 125 ms, TI: 2350 ms, 250 × 250 mm2 field of view (FOV), 132
sagittal slices, 0.98 × 0.98 × 1.2 mm3 voxel resolution) and a 3D T1-weighted
fast spoiled gradient echo (FSPGR) sequence (TR 7.8 ms, TE 3 ms, FA 12°,
240 × 240 mm2 FOV, 176 sagittal slices, 0.94 × 0.94 × 1 mm3 voxel resolution).
Reference WM lesion segmentations were constructed manually using the 3D
FLAIR and 3D T1-weighted images by a highly trained neuroradiological team
(Steenwijk et al., 2013). In short, both 3D T1-weighted and 3D FLAIR images
were co-registered and orthogonally reformatted to the axial plane, and the
5http://mipav.cit.nih.gov/
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axially reformatted images were then used to identify and outline the lesions.
Lesion identification was performed by three raters in consensus using the 3D
FLAIR images; the raters were allowed to view the corresponding co-registered
3D T1-weighted image. Lesions were only identified if they were larger than 3
voxels in-plane and visible on at least two consecutive slices. In the next step,
two trained technicians manually outlined the identified lesions on the 3D FLAIR
using MIPAV. The expert lesion segmentation resulted in a wide range of lesion
volumes going from 1.88 to 50.95 ml, with a mean of 16.33 ml and a standard
deviation of 11.49 ml. For comparison purpose, these lesion segmentations were
resampled from the FLAIR image space to their corresponding T1-weighted
image space using nearest neighbour interpolation as implemented in NiftyReg.
Dataset 2
Dataset 2 contains scans from 10 MS patients scanned twice, with re-positioning
(time interval between two scans is 5 ∼10 minutes), on each of three different 3T
scanners from GE (Discovery MR750w), SIEMENS (Skyra) and PHILIPS
(Achieva). The protocol contained two 3D sequences: T1-weighted and
FLAIR, and their details are described in table 2.1. For this dataset, no
expert segmentations were available. Also, the resolution of T1-weighted and
FLAIR images from all the scanners is high and therefore, due to very high
computational memory requirement, none of the methods were able to run
on these high resolution images; therefore, the T1-weighted image was down
sampled to (1 × 1 × 1 mm3) resolution. The FLAIR image was not down
sampled at this point because it is rigidly co-registered to T1-weighted image
in the initial stage of the method and thus will have the T1-weighted image
resolution. This study was carried out in accordance with the recommendations
of the ‘International Conference on Harmonisation of Good Clinical Practice
(ICH-GCP)’, and the applicable Belgian and Dutch legislation. The study was
approved by the UZ Brussels ethical committee. All subjects gave written
informed consent in accordance with the Declaration of Helsinki.
2.2.4 Performance tests
Comparison to expert segmentations on dataset 1
For dataset 1, the agreement between automatic methods and expert reference
segmentation is evaluated at a voxel-by-voxel level. Spatial agreement is reported
by the Dice similarity index [43]), defined as the ratio between the number of
voxels where both the automatic and the expert reference segmentation agree
(true positives) and the mean number of voxels labelled as lesion by the two
methods. Additionally for dataset 1, the average Dice performance for each
28 SINGLE TIME POINT MS LESION SEGMENTATION
Table 2.1: Dataset 2 sequences description for all three scanners.
Sequence TR (ms) TE (ms) TI (ms) FOV (mm2) Voxel size (mm3) No. of slices (sagittal)
GE
3D T1-weighted FSPGR 7.32 3.14 NA 220 × 220 0.43 × 0.43 × 0.50 328
Fat saturated 3D FLAIR 9500 135.78 2428 240 × 240 0.47 × 0.47 × 0.70 232
SIEMENS
3D T1-weighted MPRAGE 2300 2.29 NA 240 × 240 0.94 × 0.94 × 0.94 176
Fat saturated 3D FLAIR 5000 387 1800 230 × 230 0.45 × 0.45 × 0.90 192
PHILIPS
3D T1-weighted FSPGR 4.93 2.3 NA 230 × 230 0.53 × 0.53 × 0.50 310
Fat saturated 3D FLAIR 4800 276 1650 240 × 240 1.04 × 1.04 × 0.56 321
NA = Not available.
method is computed separately for patients with small, medium and large lesion
volumes in order to assess whether the methods’ performance is depending on
lesion volume. For the total lesion volume, agreement between automatic and
expert reference segmentation is evaluated through the intra-class correlation
coefficient (ICC) and the absolute volume difference. ICC is a measure assessing
the agreement of measurements made by multiple observers measuring the same
quantity [93]. In this chapter, ICC is used in the absolute agreement formulation.
The absolute volume difference is computed as the absolute difference between
the total volume reported by the automatic method and the corresponding
value derived from expert reference segmentation.
For dataset 1, the automatic methods segmentation quality is evaluated at a
voxel-by-voxel level. The ability to segment lesions is reported by sensitivity
and is defined as the ratio between true positives and the total number of
lesion voxels in the expert reference segmentation (true positives and false
negatives). The relevance of the segmentation is measured by precision and
is defined as the ratio between true positives and the total number of lesion
voxels in the automatic segmentation (true positives and false positives). Since
MSmetrix-cross is an iterative method, the benefit gained over the iterations
is verified by reporting the Dice similarity index for dataset 1.
To determine if there is a statistical difference between MSmetrix-cross and
LST and between MSmetrix-cross and Lesion-TOADS methods’ performance,
a two tailed paired t-test is performed, except for the average Dice performance
as a function of lesion volume, where the sample size is small.
Lesion volume reproducibility assessment on dataset 2
For dataset 2, ten patients were examined twice in each scanner. For the total
lesion volume, agreement between the first and the second scan for each scanner
is evaluated through Dice similarity index and absolute volume difference. Here,
a two tailed paired Wilcoxon signed-rank test is performed instead of a t-test
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as the Dice similarity index and absolute volume difference for all methods are
not normally distributed.
2.3 Results
2.3.1 Accuracy results on dataset 1
In this section we first present quantitative results (Dice similarity index, ICC
and absolute volume difference) followed by the qualitative results, where the
segmentation results are evaluated visually by presenting the best and the worst
cases for each of the automatic methods.
Quantitative results
Table 2.2 presents the quantitative results where the Dice similarity index
reaches an average of 0.67 for MSmetrix-cross, followed by 0.61 for Lesion-
TOADS and 0.55 for LST. In order to visualise the volumetric correlation of
each automatic method to the expert reference segmentation, Figure 2.2 shows
the scatter plots for total lesion volume (lesion load) in ml of each method
compared to the volume of expert reference segmentation. MSmetrix-cross is
well correlated to the expert reference lesion volume, but has a general trend of
slightly underestimating the lesion volume compared to the expert reference
lesion segmentation. Lesion-TOADS shows an even stronger trend of volume
underestimation. The absolute volume error and total lesion volume are better
correlated to the expert reference values for LST (average 4.75 ml absolute
volume error with an ICC of 0.87) than for MSmetrix-cross and Lesion-TOADS
(5.15 ml, 0.80, and 6.8 ml, 0.63 respectively).
In order to provide a better understanding of the segmentation performance,
also the sensitivity and precision at voxel level are presented in Table 2.3 for
each of the automatic methods compared to the expert reference segmentation.
The sensitivity reaches an average of 0.57 for MSmetrix-cross, followed by
0.50 for Lesion-TOADS and for LST. MSmetrix-cross is more precise, with an
average precision of 0.83 compared to 0.70 and 0.81 for LST and Lesion-TOADS,
respectively. Table 2.4 presents the average Dice performance of each method for
patients with small, medium and large lesion volumes, computed according to
the expert reference segmentation. For this, the dataset was divided into three
intervals according to lesion load: ≤5 ml, 5–15 ml and ≥15 ml. From the table
it can be concluded that all methods show an increase in their performance for
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Table 2.2: Agreement measures (Dice similarity index, ICC and absolute volume difference)
between automatic and expert reference lesion segmentation for MSmetrix-cross, LST and
Lesion-TOADS for 20 MS patients.
Automatic method Dice ICC Absolute volume
difference (ml)
MSmetrix-cross 0.67 ± 0.11 0.8 5.15 ± 4.75
LST 0.55 ± 0.16∗∗ 0.87 4.75 ± 3.63
Lesion-TOADS 0.61 ± 0.09∗∗ 0.63 6.86 ± 5.70∗∗
Dice and absolute volume difference are presented in mean ± standard deviation.
** Values significantly different fromMSmetrix-cross (paired t-test with p < 0.01 significance level).
Figure 2.2: Scatter plots of expert reference values versus automatically computed values
for total lesion volume (ml). The three columns show results for MSmetrix-cross, LST and
Lesion-TOADS, respectively.
large lesion volume, with MSmetrix-cross being most consistent, i.e., having a
higher stable range of values among the groups.
The Dice similarity index for MSmetrix-cross grows from 0.51 ± 0.14 at
Table 2.3: Segmentation quality measures (sensitivity and precision) between automatic
and expert reference lesion segmentation for MSmetrix-cross, LST and Lesion-TOADS for
20 MS patients.
Automatic method Sensitivity Precision
MSmetrix-cross 0.57 ± 0.13 0.83 ± 0.11
LST 0.50 ± 0.22∗ 0.70 ± 0.09∗∗
Lesion-TOADS 0.50 ± 0.08∗∗ 0.81 ± 0.17
Sensitivity and precision are presented in mean ± standard deviation.
* Values significantly different from MSmetrix-cross (paired t-test with p < 0.05 significance level).
** Values significantly different from MSmetrix-cross (paired t-test with p < 0.01 significance level).
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Table 2.4: Agreement measure (average Dice similarity index) for small (n=3), medium
(n=9) and large (n=8) lesion volumes for automatic methods. Here, the t-test is not performed,
as the sample size is small for each group.
Automatic method Average Dice
(< 5) ml (5-15) ml (>15) ml
MSmetrix-cross 0.61 0.62 0.74
LST 0.33 0.51 0.69
Lesion-TOADS 0.52 0.58 0.67
iteration 1, to 0.60 ± 0.13 at iteration 2, to 0.66 ± 0.11 at iteration 3, which
proves the benefit of using the proposed iterative approach (see figure 2.1).
Stopping after iteration 3 provides a reasonable trade-off between sensitivity
and precision.
Qualitative results
In the following figures of this section, the original FLAIR image is shown
followed by the lesion segmentation from the expert reference segmentation
(yellow), MSmetrix-cross (green), LST (orange) and lesion-TOADS (red) are
super-imposed on the bias corrected FLAIR images.
Figure 2.3 shows the best case for MSmetrix-cross (Dice: 0.84, sensitivity: 0.84
and precision: 0.83),which is also the best case for Lesion-TOADS (Dice: 0.79,
sensitivity: 0.73 and precision: 0.87). This case has Dice: 0.69, sensitivity: 0.87,
and precision: 0.57 for LST. The high sensitivity and low precision of LST are
caused by the presence of false positive lesions and the overestimation of lesion
boundaries (marked by cyan arrow heads) compared to the other two methods.
Between MSmetrix-cross and Lesion-TOADS, the higher Dice similarity index
of MSmetrix-cross is because of the higher sensitivity. Notice that the lesions
marked by pink arrow heads were picked up by MSmetrix-cross but not by the
other methods except one by Lesion-TOADS.
Figure 2.4 shows the worst case for MSmetrix-cross (Dice: 0.45, sensitivity: 0.31
and precision: 0.79). LST and Lesion-TOADS had comparable performance,
namely, Dice: 0.43, sensitivity: 0.31, and precision: 0.70 for LST, and Dice:
0.47, sensitivity: 0.35, and precision: 0.73 for Lesion-TOADS. Some subtle
lesions are either missed or the lesions are underestimated (purple arrowhead).
This accounts for the low sensitivity and the low Dice similarity index for all
the methods. More examples from dataset 1 are given in the appendix A.
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Figure 2.3: Original FLAIR image (a) followed by bias corrected FLAIR image and super-
imposed lesion segmentation from: (b) expert segmentation, (c) MSmetrix-cross, (d) LST,
and (e) Lesion-TOADS. Cyan arrowheads show false positive lesions and overestimation of
the lesion boundaries in LST. Pink arrow heads show lesions picked by MSmetrix-cross but
not by the other methods except one in Lesion-TOADS.
Figure 2.4: Original FLAIR image (a) followed by bias corrected FLAIR image and super-
imposed lesion segmentation from: (b) expert segmentation, (c) MSmetrix-cross, (d) LST,
and (e) Lesion-TOADS. Purple arrow heads show some subtle lesions that are either missed
or the lesions are underestimated.
2.3.2 Reproducibility results on dataset 2
In this section, we first present quantitative results (Dice similarity index and
absolute volume difference) followed by the qualitative results, where visual
results are presented for MSmetrix-cross, LST and Lesion-TOADS.
Quantitative results
Table 2.5 presents the quantitative results where the Dice similarity index
reaches an average of 0.71 for LST, followed by 0.69 forMSmetrix-cross and
0.63 for Lesion-TOADS. The absolute lesion volume difference is less for LST
(average 0.44ml absolute volume difference) than for MSmetrix-cross and
Lesion-TOADS (0.54 and 1.58 ml respectively).
In order to visualise the volumetric agreement between scan 1 and scan 2 of the
corresponding automatic methods, Figure 2.5 contains the Bland-Altman plot
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Table 2.5: Agreement measures (Dice similarity index and absolute volume difference)
between scan 1 and scan 2 of the corresponding automatic methods.
Automatic method Dice Absolute volume
difference (ml)
MSmetrix-cross 0.69 ± 0.14 0.54 ± 0.58
LST 0.71 ± 0.18 0.44 ± 0.69
Lesion-TOADS 0.63 ± 0.17∗∗ 1.58 ± 2.2
Dice and absolute volume difference are presented in mean ± standard deviation.
** Values significantly different from MSmetrix-cross (paired t-test with p < 0.01 significance level).
Figure 2.5: Bland-Altman plots for total lesion volume agreement between scan 1 and scan 2
of the corresponding automatic methods. The three columns show results for MSmetrix-cross,
LST and Lesion-TOADS, respectively.
for total lesion volume of each method at scan 1 compared to the volume at
scan 2.
Qualitative results
In the following figures of this section, the original FLAIR image is shown
followed by the lesion segmentations from MSmetrix-cross (green), LST
(orange) and Lesion-TOADS (red) are super-imposed on the bias corrected
FLAIR images. In each figure, the first row corresponds to the lesion
segmentation of scan 1 and the second row corresponds to the lesion segmentation
of scan 2.
Figure 2.6 shows the best case (highest reproducibility) for MSmetrix-cross
(Dice: 0.84). In this case, LST has the same performance (Dice: 0.84)
as MSmetrix-cross followed by Lesion-TOADS (Dice: 0.65). A good Dice
similarity index for both MSmetrix-cross and LST is mainly due to the fact
that both methods are consistent in the lesion segmentation in their respective
scan 1 and scan 2, while Lesion-TOADS seems to differ more in its lesion
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Figure 2.6: Bias corrected FLAIR image (a) and super-imposed lesion segmentation from:
(b) MSmetrix-cross, (c) LST, and (d) Lesion-TOADS. The first row corresponds to the lesion
segmentation of scan 1 and the second row corresponds to the lesion segmentation of scan 2.
Cyan arrow heads show the difference in the lesion segmentation boundary between scan 1
and scan 2 for Lesion-TOADS.
segmentation boundary between scan 1 and scan 2 (marked by cyan arrow head)
and thus resulting in a lower Dice similarity index.
Figure 2.7 shows the worst case for MSmetrix-cross (Dice: 0.38). In this case,
Lesion-TOADS has the best performance (Dice: 0.52) followed by LST (Dice:
0.46). The low Dice similarity index for MSmetrix-cross is caused by false
lesion detection in either of the scans (marked by cyan arrow heads). The
higher Dice similarity index for Lesion-TOADS compared to MSmetrix-cross
and LST is mainly due to its quite consistent performance in detecting both
true and false lesions in scan 1 and scan 2 (marked by pink and cyan arrow
heads) for this case. For LST, a lower Dice similarity index is mainly due to
the fact that it detects several few false lesions in either of the scans (marked
by cyan arrow heads). However, both MSmetrix-cross and Lesion-TOADS are
more sensitive and thus detect subtle lesions (marked by pink arrow heads)
whereas LST misses them in most of the cases (marked by purple arrow head).
More examples from dataset 2 are given in the appendix A.
2.4 Discussion and conclusions
In this chapter, a robust method for WM lesion segmentation is proposed,
incorporating a lesion-filling algorithm for T1-weighted images and an iterative
process of using the lesion-filled T1-weighted image for WM/GM/CSF tissue
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Figure 2.7: Bias corrected FLAIR image (a) and super-imposed lesion segmentation from:
(b) MSmetrix-cross, (c) LST, and (d) Lesion-TOADS. The first row corresponds to the lesion
segmentation of scan 1 and the second row corresponds to the lesion segmentation of scan 2.
Cyan arrowheads show the difference in the lesion segmentation between scan 1 and scan2 for
MSmetrix-cross, LST and Lesion-TOADS. Pink arrow heads show subtle lesions that are
picked up by MSmetrix-cross and Lesion-TOADS. Purple arrow head shows missed subtle
lesions by LST.
segmentation and the FLAIR image for lesion detection and segmentation. The
method is fully automatic and has proven to be robust for different scanners
without parameter tuning. As opposed to previous work [176, 146], where multi-
channel images were used simultaneously for lesion segmentation, we adopt an
approach that tries to imitate more the human expert. In our case, T1-weighted
and FLAIR images are used independently in order to fully exploit the main
characteristics of each modality. In this chapter, the method is evaluated for
3D T1-weighted and 3D FLAIR MR images. However, first visual assessment
of the methods’ performance with 3D T1-weighted and 2D FLAIR MR images
indicates good results.
The problem of MS lesion segmentation has received interest in the research
community for the past 15 years (see [61, 108] for recent reviews). Although WM
lesions are visible on the FLAIR image, automatic detection and delineation
remain very challenging. The differentiation of MS lesions from ‘dirty’ WM
and CSF pulsation artefacts in FLAIR is very difficult, as they share typical
spatial locations and appear similar to MS lesions. Moreover, the MS lesions
that are visible on FLAIR images exhibit very high pixel intensity variations,
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thus lesions can be classified as hyper- or hypo-intense. While it is quite easy
to identify hyper-intense lesions, for example by intensity thresholding, hypo-
intense lesions, on the other hand, are iso-intense with GM intensities and thus
pose a challenge.
Manual lesion segmentation is time-consuming and suffers from inter- and intra-
rater variability, with studies reporting low variability of total lesion volume
estimation only in ideal situations, e.g., when lesion detection is done by a
single observer and lesion delineation is performed by multiple raters, aided by
the same semi-automated software tool ([52]: coefficient of variation of 2.3% for
intra-observer and 2.9% for inter-observer). However, such good results are not
reproduced in the realistic situation when lesion detection and delineation are
done by experts in different centres; as an example, MR images from 24 MS
patients have been segmented by 2 experts for the MICCAI 2008 challenge6
and variability reached a relative volume difference of 68% and a percentage
of false negatives (number of lesions marked by one rater only) of 32%, as
reported by [61]; section 5.3. Semi-automatic lesion segmentation could mean
that lesion detection is done by the expert user and an automatic method for
‘lesion growing’ (i.e., lesion segmentation) is applied afterwards. This approach
is more consistent than manual delineation, but still time consuming and not
reproducible.
Automatic methods have the obvious advantage of being consistent and fast
when compared to manual or semi-automatic methods [179]. These automatic
methods can broadly be classified into supervised and unsupervised category.
As previously described in the introduction section (1.5.1), supervised methods
require a training dataset and perform well only when the new image to be
segmented is well represented in the training dataset. On the other hand,
unsupervised methods such as our proposed method, LST and Lesion-TOADS
do not require training images. They perform brain segmentation into GM, WM
and CSF (with or without lesion detection) and often rely on post-processing
approaches in order to segment lesions (e.g., lesion growing or pruning). The
assumptions that are made in order to segment lesions have a great impact on the
results. From this point of view, MSmetrix-cross has similarities to LST, since
both methods detect FLAIR-hyper-intense outliers, which are further promoted
as lesions according to their spatial probability of being in the WM, where the
WM segmentation is basically derived from T1-weighted image segmentation.
Nevertheless, MSmetrix-cross’s iterative process is meant to allow a more
reliable estimation of the WM mask, as the WM/GM/CSF segmentation of
the lesion-filled T1-weighted image should improve at each iteration. Lesion-
TOADS, on the other hand, employs a sophisticated mechanism of combining
information from different MR sequences (T1-weighted, T2, PD or FLAIR) in
6http://www.ia.unc.edu/MSseg/
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order to simultaneously segment lesions and brain structures, while distance
maps from the boundaries of structures such as CSF are used to confine the
segmented lesions to typical locations. These mechanisms are bound to have
a large number of parameters that require tuning. The effect of keeping all
parameters to their default values was obvious when comparing results of Lesion-
TOADS on dataset 1 and 2. Dataset 2 images were not as good as those from
dataset 1 (based on visual quality control of input images), which translated
into a significant decrease in segmentation performance of Lesion-TOADS in
dataset 2. Based on visual quality control of the resulting segmentations, Lesion-
TOADS introduced a large amount of false positives, which was not the case in
dataset 1.
An important contribution of this work is the experimental validation of
MSmetrix-cross, both for accuracy and reproducibility. On dataset 1, which
was used for the evaluation of the segmentation accuracy, we could observe that
MSmetrix-cross has a reasonably good overlap with the expert segmentation,
but with some systematic undersegmentation. The fair sensitivity of MSmetrix-
cross suggests that it can segment subtle lesions reasonably well but still misses
small lesions (lesions that are less than five voxels or lesions appearing on a
single slice) or lesions at the border between GM and WM due to imperfect
tissue segmentation. However, MSmetrix-cross is quite consistent in segmenting
small, medium and large lesions. False positive lesions are mostly found near the
frontal horn, in the posterior end of the corpus callosum, also known as splenium,
and in the cortical region near the great longitudinal fissure. On dataset 2, the
reproducibility of the segmentation as well as the lesion volumes were evaluated,
as the reproducibility on the test-retest data is a very important aspect to check
the consistency and reliability of the results. The main sources of inconsistency
are differences in the estimation of the lesion boundaries between both scans
and differences in detecting smaller (often false) lesions (see e.g., Figure A.4 in
the appendix A).
The comparison with the existing lesion segmentation tools, LST and Lesion-
TOADS, shows the outperformance of MSmetrix-cross regarding the accuracy
of the lesion segmentation. The Dice similarity index with respect to the expert
reference segmentation is significantly higher for MSmetrix-cross than for LST
(p<0.01) and Lesion-TOADS (p<0.01). Looking in more details, this could
mainly be explained by the significantly higher precision compared to LST
(p<0.01) and the significantly higher sensitivity compared to Lesion-TOADS
(p<0.01) as well as LST (p<0.05). LST, however, has a slightly lower average
absolute volume error, although not significantly. This suggests that it misses
lesions or hypo-intense lesions (see e.g., Figure 2.4) and compensates for these
missed lesions’ volume by overestimating other, mostly larger, lesions (see
e.g., Figure 2.3). This also explains the increase in segmentation overlap
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performance of LST as a function of the lesion load. Additionally, LST
often introduces false lesions in the corpus callosum (see e.g., Figure A.1 in
the appendix A). For Lesion-TOADS, the comparable precision but a lower
sensitivity compared to MSmetrix-cross, implies a larger amount of false
positives within the Lesion-TOADS segmentation. It suffers from false lesions
segmentation, which is, unlike MSmetrix-cross, randomly distributed in the
image (see e.g., Figure A.2 in the appendix A) and is less accurate in segmenting
the lesion boundary when compared to MSmetrix-cross. Lesion-TOADS, like
LST and MSmetrix-cross, also shows an increase in the segmentation overlap
with expert segmentation as a function of lesion load.
The first dataset presented in this chapter, including expert reference
segmentations, was also used in [160], which means that it is possible to directly
compare results herein to those published in [160]. The results in [160] may
in fact be regarded as a best-case scenario, because the k-nearest neighbour
classification employed therein is a supervised classification technique that was
trained using a leave-one-out experiment on the 20 patients of dataset 1, based
on the available expert reference segmentation. An optimal configuration has
been sought and post-processing has been applied to reduce the number of small
false positive regions. The average Dice similarity index reached a maximum
of 0.75 ± 0.08 after optimal post-processing. Volumetric correspondence in
terms of ICC was 0.93 after post-processing. These numbers can be compared
to the MSmetrix-cross, LST and Lesion-TOADS results in Table 2.2, keeping
in mind that these methods are unsupervised and did not require any tuning or
post-processing on this particular dataset.
Regarding the reproducibility of the lesion segmentation, we found a similar
overlap as well as a similar absolute lesion volume difference between MSmetrix-
cross and LST. Both automatic methods have almost identical limits of
agreement (see e.g., Figure 2.5). In contrast, Lesion-TOADS shows much
larger limits of agreement indicating clearly lower lesion volume reproducibility.
Similar to MSmetrix-cross, Lesion-TOADS is not very consistent in introducing
false positive lesions in two consecutive scans (see e.g., Figure 2.6), and, secondly,
it is not as sensitive as MSmetrix-cross in segmenting the lesion boundaries in
the test-retest scans (see e.g., Figure 2.6).
In conclusion, the proposed automatic lesion segmentation method, MSmetrix-
cross, has been demonstrated to provide more accurate lesion segmentations
with a similar reproducibility compared to the state-of-the-art software tools.
We believe that, through its robustness and automation, MSmetrix-cross could
bring an added value (possibility to measure lesion volumes) for the clinical
routine evaluation of MS patients.
Chapter 3
Patch-based
super-resolution of MRSI:
Application to MS
Abstract
MRSI provides complementary information to conventional magnetic resonance
imaging. Acquiring high-resolution MRSI is time consuming and requires
complex reconstruction techniques. In this chapter, a patch-based super-
resolution method is presented to increase the spatial resolution of metabolite
maps computed from MRSI. The proposed method uses high-resolution
anatomical MR images (T1-weighted and FLAIR) to regularise the super-
resolution process. The accuracy of the method is validated against conventional
interpolation techniques using a phantom, as well as simulated and in vivo
acquired human brain images of multiple sclerosis subjects. We showed that the
method preserves tissue contrast and structural information, and matches well
with the trend of acquired high-resolution MRSI. These results suggest that the
method has potential for clinically relevant neuroimaging applications.
The work presented in this chapter has been published in: Jain, S., Sima, D.M., Sanaei Nezhad, F., Hangel,
G., Bogner, W., Williams, S., Van Huffel, S., Maes, F. and Smeets, D. Patch-based super-resolution of MR
spectroscopic images: Application to Multiple Sclerosis Frontiers in Neuroscience 11: 13 (2017), 12 pages.
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3.1 Introduction
MRSI of the brain provides information on the chemical composition of tissues
and may reveal underlying metabolic changes that are not visible on conventional
MRI such as T1-weighted MRI. For example in MS, MRSI can show the extent
of damage in normal appearing white matter and therefore is more sensitive
in detecting pathological changes compared to conventional MRI [50, 136].
Additionally, metabolite concentrations in normal appearing brain tissue are
better correlated with clinical scores than MRI lesion load [139].
As mentioned in the introduction section 1.7.4, MRSI has poor spatial resolution
(typically around 1 cm3) which limits the ability to differentiate among spatial
features of interest, e.g., between different tissue types. High spatial resolution
MRSI cannot be acquired in the clinical routine with standard acquisition
sequences as it requires a long scanning time.
Therefore, there is a need to design alternative, non-conventional approaches to
create high-resolution MRSI-based metabolic images within a limited acquisition
time. The acquisition time can be reduced by optimising the conventional phase
encoded MRSI protocol [1, 118, 122] or by using parallel imaging reconstruction
based techniques [47, 100, 115, 7] or combination of both [45], see [121] for a
detailed review. Conventional MRSI protocols contain a series of periodic spatial
and spectral encoding schemes. These could be optimised by reading out the
spatial information during spectral acquisition. This optimised technique forms
the basis of the echo planar spectroscopic imaging (EPSI) [122] which provides
an improved spectral and spatial resolution compared to conventional MRSI
protocols for fields up to 3T. Derived from the EPSI technique, spiral MRSI
[1, 4, 19] uses a spiral trajectory in k-space, which allows faster acquisition than
EPSI however at the cost of increased complexity in the data reconstruction.
Parallel imaging reconstruction techniques are based on the principle of acquiring
multiple undersampled k-space data using phased array coils. This undersampled
data is then reconstructed into a single image using techniques like SENSE [127]
or GRAPPA [71]. These techniques exploit the difference in spatial sensitivity
among receiver coils to reconstruct an image from the undersampled data. Since
optimised MRSI protocols like EPSI and parallel imaging are independent in
nature, they can be combined to further reduce the acquisition time [45]. This
reduction in the acquisition time generally comes at the cost of decreased SNR
in the data. In spite of advances in speeding up the MRSI acquisition these
techniques are yet not clinically feasible as the time required to attain the
spatial resolution of conventional MRI sequences such as T1-weighted imaging
still remains very high, although approaches that combine phase-encoding and
EPSI [102] appear quite promising.
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An ultra-high magnetic field strength such as 7T (used for non-routine research)
offers more SNR, but the inherent limitations (e.g., related to specific absorption
rate (SAR) or B0/B1 homogeneity) have complicated high-resolution MRSI
acquisition until the recent years. Free induction decay (FID) MRSI [18,
123, 161] with short acquisition delays was proposed to avoid SAR-intensive
localisation schemes and SNR-loss due to T2∗ decay. The application of parallel
imaging like SENSE [92, 186], GRAPPA [73] or CAIPIRINHA [162] allowed
acceleration factors up to 9. Combining parallel imaging with a short TR of
200 ms, the acquisition of high-resolution MRSI within a 128×128 mm2 field of
view with a voxel volume of 23 µL and full slice coverage in around 10 minutes
was successfully demonstrated in [74].
An alternative is to increase the MRSI resolution by super-resolution (SR)
techniques. Super-resolution methods include k-space based reconstruction
methods that improve the spectral quality of reconstructed high-resolution
MRSI data using high-resolution spatial features, such as edges, from other
imaging modalities, in particular T1-weighted MRI (for a detailed review see
[89]). Super-resolution methods can be categorised into two sub-groups: methods
based on a linear regression framework, or on a Bayesian framework. Linear
regression based SR methods (LRSR) assume that the acquired data can be
explained by a linear combination of a set of independent variables. Therefore,
they aim at optimising the coefficients of these independent variables such that
the error between the predicted and the actual measurements is minimised.
One such method is spectral localisation by imaging (SLIM) [76] which assumes
that the high-resolution MRSI consists of a linear combination of L anatomical
compartments that are spectrally homogeneous. Although easy to implement,
the assumption of spectral homogeneity may not hold true. To cope with
this, two extensions have been proposed: generalised SLIM (GSLIM) [99] and
SLIM with explicit B0 field inhomogeneity compensation (BSLIM) [90]. GSLIM
uses spatial Fourier harmonics to absorb any spatially dependent spectral
variations and BSLIM assumes that the spectral variations are solely due to
local (static) field inhomogeneity, therefore, requires an additional B0 map for
its correction. It has been observed that simple LRSR methods not always result
in physically plausible solutions, therefore, an additional term commonly known
as ‘regulariser’ is added to the optimisation problem so that the reconstruction
remains well-behaved. For example, in [80], a local B-spline basis function is
added as a regulariser to the GSLIM model to allow local intensity variations
within each compartment. In [72], a smoothness regularisation term (controlled
by pre-computed anatomically derived weight factors) has been added to penalise
the local spectral variation between neighbouring voxels. The second sub-group
of methods are based on Bayesian theory and model the reconstruction in the
k-space as a likelihood function where the anatomical information acts as prior
knowledge to estimate the optimised model parameters via the expectation-
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maximisation algorithm. For example in [8], the likelihood function consists of
a combined spectral-spatial model where the tissue segmentations acts as prior
information in estimating additional high frequencies in k-space. As an extension
of this work, the likelihood model in [94] also addresses the spectral fitting
problems and additionally uses prior information on the relationship between
tissue segmentation and spatial metabolite distribution. These Bayesian based
models are very complex in nature and have many variables to be optimised
that often result in locally optimal solutions.
Contrary to the k-space based super-resolution approaches presented above,
patch-based super-resolution (PBSR) methods have been used to reconstruct
high-resolution T2 and diffusion weighted MR images [103, 104, 135, 34] in
the spatial domain using a high-resolution T1-weighted image as reference.
PBSR methods are based on the principle of image redundancy (ability to find
similar patches in an image) and aim at finding similar voxels (defined using self
similarity or using the high-resolution image (e.g., T1-weighted image)) in the
neighbourhood of the central voxel that could be used to guide the reconstruction
of the central voxel. As opposed to classical interpolation methods (nearest
neighbour, linear interpolation and B-splines), PBSR method provides better
tissue contrast and thus yields better image quality reconstructions.
In view of good performance of PBSR methods in upsampling T2 and diffusion
weighted MR images, we propose a multi parametric patch-based super-
resolution method that acts directly on quantified MRSI metabolite maps from
low-resolution MRSI data. In addition to the conventionally used high-resolution
T1-weighted image, a FLAIR image is also used for lesion segmentation in
multiple sclerosis subjects. The reconstruction process is guided by the intensities
of T1-weighted and FLAIR images along with the brain segmentation, thus
providing better estimation of brain tissue boundaries. To the best of our
knowledge, a PBSR technique has never been applied before for upsampling
MRSI-based metabolic images. We compare our method against the classical
upsampling methods (nearest neighbour, linear interpolation and B-splines)
on (a) an acetate image from a phantom, which contains different acetate
proportions in different spatial locations, (b) simulated MS brain and quantified
N-acetylaspartate images and (c) real images of MS patients with quantified
N-acetylaspartate and myo-inositol images.
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3.2 Methods
3.2.1 Method description
The patch-based super-resolution pipeline upsamples the low resolution
quantified MRSI metabolite map using the high-resolution T1-weighted and
FLAIR MR images. In the next sections, we describe the pipeline that has
three steps:
1. a preprocessing step, including (a) MRI brain tissue segmentation, (b)
metabolite quantification, (c) super-resolution initialisation.
2. a reconstruction step that estimates the metabolite concentration at each
higher resolution MRSI voxel using the tissue segmentations along with
image intensities of bias corrected T1-weighted and FLAIR images.
3. a mean correction step that rectifies the estimated metabolite concentra-
tion in every high-resolution voxel by taking into account a point spread
function (PSF) and the error towards the corresponding lower level voxel’s
metabolite value.
The method iterates between step 2 and step 3 such that the corrected metabolite
concentration map from previous iteration is used to initialise the metabolite
concentration prior map for the current iteration. The convergence of our method
is detected when the relative metabolite concentration difference between the
current and previous iteration is negligible. It takes generally five iterations for
the algorithm to converge. An overview of the pipeline is shown in figure 3.1.
Preprocessing
MRI brain tissue segmentation
The anatomical brain MR images are segmented into GM, WM, CSF and lesions
using MSmetrix-cross (see chapter 2). The method iteratively segments the
T1-weighted image into GM, WM, and CSF, segments the WM lesions on the
FLAIR image as an outlier to normal brain using Mahalanobis distance, and
performs lesion filling in the T1-weighted image to improve tissue segmentation
at next iteration. After convergence, soft segmentations of GM, WM and CSF
are created together with binary lesion segmentation. In addition, bias corrected
T1-weighted and FLAIR images are also produced.
Metabolite quantification
The acquired MRSI data, after Fourier transformation from k-space to the
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Figure 3.1: Schematic representation of patch-based super-resolution pipeline.
spatial domain, can be fitted in a voxel-by-voxel fashion using a simulated
metabolite basis set, matching the acquisition parameters (e.g., echo time) of
the given signals. The fitting can be based either on time-domain MRSI signals,
or after Fourier transformation to the frequency domain. In this work we used
the SPID software1 [173] and LCModel2 [126] for metabolite quantification.
The output consists of a set of metabolite images (‘metabolite maps’), as many
as metabolites in the basis set, and having the same spatial resolution as the
input MRSI grid.
Super-resolution initialisation
The super-resolution pipeline is initialised by (1) upsampling the low resolution
metabolite map using linear interpolation (scale factor of 2). This forms the
starting value of the high-resolution MRSI metabolite map, (2) by aligning the
MRI and MRSI images. As the MRI and MRSI images are acquired on the
same scanner and in a sequential manner, their affine transformations are used
to project the MRI image along with the tissue segmentations into the space of
the upsampled MRSI image. The total affine transformation that relates these
two image spaces is defined as:
Totalaffine = MRSI−1affine.MRIaffine (3.1)
1SPID:http://homes.esat.kuleuven.be/~biomed/software.php
2LCModel:s-provencher.com/pages/lcmodel.shtml
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Patch-based super-resolution
Background
Let y be a noise-free low resolution metabolite map and x be the unknown
corresponding high-resolution metabolite image defined over a high-resolution
voxel space Ω. Theoretically,
y = H(x) (3.2)
where H is a known blur and downsampling operator. In order to reconstruct x
given y, the reconstruction model is typically formulated as an Euler Lagrange
energy minimisation problem:
xˆ = arg min{ ||y −H(x)||2︸ ︷︷ ︸
least squares fitting
+ λ R(x)︸ ︷︷ ︸
regulariser
} (3.3)
where the parameter λ controls the amount of regularisation and the R(x) term
preserves geometry and regularity and is defined as:
R(x) =
∑
i∈Ω
||xi − E(xi|ζi)||2 (3.4)
E(xi|ζi) is the conditional reconstruction of xi based on voxel intensity values
in the ‘search volume’ ζi and is empirically defined as a cube of size 9× 9× 9
voxels around the centre voxel xi.
We assume that the term E(xi|ζi) is consistent under strictly stationary
conditions, i.e., this stationary condition amounts to saying that, as the
resolution of the image increases, there are many similar patches for all the
details of the image. Also, when the regions move far from each other, their
correlation decreases [23]. Both assumptions are approximately met in the case
of MRSI. If E(xi|ζi) is modelled under these assumptions, then xi → E(xi|ζi)
which means R(x) → 0 [134]. Therefore, the two terms of the energy functional
can be decoupled and asymptotically approximated as the reconstruction and
mean correction steps of the iterative super-resolution algorithm.
Algorithm : SR(y = low res image; x = starting value for high res image)
while |xti − xt−1i | > , ∀ xi ∈ x
Reconstruction : xt+1i = E(xi|ζi), ∀ xi ∈ x
Mean correction : xˆit+1 = xt+1i − (yp −H(xt+1i )︸ ︷︷ ︸
error
)
where p is the index of the corresponding voxel at low resolution of which xi is
a part.
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Reconstruction
The reconstruction term, E(xi|ζi) in its general form is defined as:
E(xi|ζi) =
∑
j∈ζi
w(xi, xj)xj (3.5)
where the weight w(xi, xj) defines the contribution of neighbourhood voxel xj
in the reconstruction of xi. Mathematically, the general form of w(xi, xj) is
defined as [34]:
w(xi, xj) =
1
Zi
e
− 12N
(
||Nˆi−Nˆj ||
hi
)2
(3.6)
where Zi is a normalisation constant such that
∑
j∈ζi
w(xi, xj) = 1, Nˆi is the
intensity vector of the local neighbourhood Ni of length N , hi is the standard
deviation of neighbourhood voxel intensities in Ni. Ni is empirically defined
as a cube of size 3× 3× 3 voxels around the centre voxel xi. From equation-
3.6, we observe that if Nˆj is similar to Nˆi, more weight is given to xj in the
reconstruction of xi. Since we use both high-resolution MRI (T1-weighted and
FLAIR) and low resolution MRSI, the weights are refined for both modalities
taking into account the prior information:
Refining the weights for high-resolution MR images
wMRI(xi, xj) are defined such that the weights in (3.6) accommodate the prior
knowledge on brain tissue segmentations that were down-sampled to match the
MRSI resolution:
wMRI(xi, xj) =
1
Zi.K
K∑
k
pi,k.pj,k.e
− 12N
(
||Nˆi−Nˆj ||
hi
)2
(3.7)
where k ∈ K = {GM, WM, CSF}, p.,k denotes the probability that the voxel
belongs to a particular tissue class k.
Refining the weights for low resolution MRSI
The wMRSI(xi, xj) weights have the form (3.6), and the only unknown term is
hi. Assuming white noise Gaussian distribution, hi can be calculated using the
pseudo residuals i:
i =
√
6
7(xi −
1
6
∑
n∈N∗
i
xn) (3.8)
where N∗i is the 6-neighbourhood (4 in-plane and 2 out-of-plane neighbours) of
xi. Now,
h2i =
1
M
∑
j∈N∗
i
2j (3.9)
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where M is the number of voxels in N∗i .
After computing weights for both modalities, E(xi|ζi) is defined similar to [135]:
E(xi|ζi) =
∑
j∈ζi
{
(1− α(xi))wMRI + α(xi)wMRSI
}
xj (3.10)
where α(xi) is a weighing term between the MRI and MRSI weights. The choice
of α(xi) is application specific. For example, in case of non-pathological studies,
the reconstruction process could be driven by MRI only, and therefore, α(xi)
can be set to zero. In case of pathological cases like MS, MRSI is more sensitive
to pathological changes such as lesions compared to MRI. As we focus on MS
subjects in this chapter, α(xi) is defined using binary lesion segmentation which
was obtained in the preprocessing step (see 3.2.1). In particular, the weight α
is defined for each voxel xi such that the α(xi) = 1 implies that it is a lesion
and thus the reconstruction process is driven by MRSI only. Otherwise, it is
driven by MRI (see equation 3.10).
Mean correction
In the mean correction step of the algorithm, the reconstructed values are first
convolved with the PSF, which is typically a sinc function (sinc(pix), where
x = 1nominal voxel size =
no of phase encoding steps
field of view ) [121, 38]. Then, the average of
the PSF corrected reconstruction values that compose the low resolution voxel
yp (of which xi is part) must be close to the corresponding original value of
the low resolution image. This corresponds to a sinc and boxcar operator
for H in (3.2), but it could be easily replaced by a general smoothing and
downsampling operator H.
3.2.2 Comparison with state-of-the-art methods
We compare our method’s accuracy against three conventional interpolation
techniques: nearest neighbour, linear interpolation and B-splines. The nearest
neighbour (NN) function assigns the value of the new point with the closest old
neighbour value. Linear interpolation (LIN) function linearly interpolates the
new point between the old points. B-splines interpolation (BS) function uses
piecewise cubic polynomials of degree 3 to interpolate the new point using four
old points (two on each side of the new point).
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3.2.3 Data
Phantom data
A cylindrical phantom (180 mm diameter, 168 mm height) is used, consisting of
7 small cylinders each having a diameter of 40 mm and depth of 150 mm, going
through the thickness of the phantom as shown in figure 3.2. The first cylinder
was kept empty for orientation purposes, followed by the second cylinder having
acetate (Ace) concentration of 6 mM. Then, the Ace concentration was increased
by 2 mM for each next cylinder resulting in a concentration of 16 mM for the
last cylinder. The rest of the empty space in the phantom was filled with water.
MR imaging was performed on a 3T whole body scanner (Philips Achieva, Best,
the Netherlands). The protocol contained two sequences: 3D T1-weighted fast
field echo sequence (TR = 6.6 ms, TE = 3.12 ms, FA = 9°, 180×180 mm2
FOV, 3 axial slices, 0.8×0.8×10.0 mm3 voxel resolution) and the 1H MRSI
point resolved spectroscopy (PRESS) sequence (TR = 1500 ms, TE = 120
ms, 300×300 mm2 FOV, 3 axial slice, 10×10×10 mm3 voxel resolution). MRI
individual cylinder segmentation was performed manually using the Slicer3
tool (version 4.3.1) and the super-resolution method was then performed at
three different higher resolution voxel sizes: 5×5×5 mm3, 2.5×2.5×2.5 mm3
and 1.25×1.25×1.25 mm3. As the phantom is homogeneous, we present in this
chapter only the phantom data results at 1.25×1.25×1.25 mm3 voxel resolution.
MRSI data was quantified using the SPID software to obtain metabolite images
for Ace.
Simulated brain datasets
The BrainWeb phantom datasets4 [30] represent a human brain and contains
three MS brain phantom images with mild, moderate and severe lesion volume.
The protocol contained two sequences: 3D T1-weighted SFLASH sequence (TR
= 18 ms, TE = 10 ms, FA = 30°, 181×181 mm2 FOV, 217 sagittal slices,
1×1×1 mm3 voxel resolution, 1% noise level and 20% RF field inhomogeneity)
and custom simulated 3D FLAIR IR sequence (TR = 8000 ms, TE = 165
ms, TI = 1800 ms, FA = 90°, 181×181 mm2 FOV, 217 sagittal slices, 1×1×1
mm3 voxel resolution, 1% noise level and 20% RF field inhomogeneity). MRI
tissue segmentation was performed using MSmetrix-cross and these tissue
segmentations were then used to simulate a high-resolution N-acetylaspartate
(NAA) map (1×1×1 mm3 voxel resolution) in the phantom brain images. In
our study, the NAA concentration was chosen to be 30 (arbitrary units) in GM,
3Slicer:www.slicer.org
4http://www.bic.mni.mcgill.ca/brainweb
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25 in WM and 20 in lesions. White Gaussian noise N (0, 2) is then added to the
simulated high-resolution NAA map and the resulting image was downsampled
using edge preserving Chebyshev type-I filter (n=31) to create a low resolution
NAA map (2×2×2 mm3 voxel resolution). MRI tissue segmentations were also
downsampled by a scale factor of 2 to match the NAA map’s low resolution.
Human datasets acquired in vivo
Five MS patients (4 females, 1 male, age 32–46) participated in the study at
the High Field MR Centre, Department of Biomedical Imaging and Image-
guided Therapy, Medical University of Vienna, Austria. This study was carried
out in accordance with the recommendations of the ‘International Conference
on Harmonisation of Good Clinical Practice (ICH-GCP)’, and the applicable
Austrian legislation. The study was approved by the Institutional Review Board
ethical committee. All subjects gave written informed consent in accordance
with the Declaration of Helsinki. All measurements were performed on a 7T
whole body MR scanner (Magnetom, Siemens Healthcare, Erlangen, Germany)
with a 32-channel receive coil array head coil (Nova Medical, Wilmington, MA,
USA). The protocol contained four sequences: (1) 3D T1-weighted MPRAGE
sequence (TR = 3800 ms, TE = 3.54 ms, FA = 9°, 230×230 mm2 FOV, 208 axial
slices, 0.7×0.7×0.7 mm3 voxel resolution), (2) 3D SPACE FLAIR sequence
(TR = 8000 ms, TE = 272 ms, FA = 160°, 215×215 mm2 FOV, 160 axial
slices, 0.8×0.8×0.8 mm3 voxel resolution), (3) low resolution 1H CAIPRINHA-
accelerated phase-encoded FID-MRSI sequence [162] (TR = 600 ms, TE = 1.3
ms, 220×220 mm2 FOV, single axial slice, 3.4×3.4×8.0 mm3 voxel resolution,
an acceleration factor of 6, 5 min measurement time), and (4) high-resolution
1H CAIPRINHA-accelerated phase-encoded FID-MRSI sequence (TR = 200 ms,
TE = 1.3 ms, 220×220 mm2 FOV, single axial slice, 2.2×2.2×8.0 mm3 voxel
resolution, an acceleration factor of 4, 6 min measurement time). Both low and
high-resolution MRSI data was acquired with WET (water suppression enhanced
through T1 effects) water suppression technique. MRI tissue segmentation was
performed using MSmetrix-cross and MRSI data was quantified using the
LCModel (version 6.3-1) to obtain metabolite images for NAA and myo-inositol
(myo-Ins).
3.2.4 Performance tests
In order to avoid the need of absolute quantification for the phantom data,
we compare ratios between the estimated metabolite values obtained by each
method in cylinders 5 and 2, and 7 and 3, respectively, as we know that the
ground truth ratio is equal to 2.
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For validating the accuracy on the simulated brain datasets and on the human
datasets acquired in vivo, the global image similarity is measured with the
structural similarity index (SSIM) [180] which is more compatible with the
human visual assessment and is defined as:
SSIM(x, y) = (2µxµy + c1)(2σx,y + c2)(µ2x + µ2y + c1)(σ2x + σ2y + c2)
(3.11)
where (µx, µy) and (σx,σy) are the respective means and standard deviations
of image x and y. In our case, the metabolite concentrations are not zero or
close to zero within brain, therefore, the stability constants c1 and c2 were set
to zero.
Additionally, for both the simulated brain and the human brain acquired in
vivo, statistical differences in the metabolite concentrations between the lesions
and their neighbouring WM tissue are tested using Welsh’s t-test [182] and the
magnitude of this difference i.e., the effect size is measured using Cohen’s d
[31].
3.3 Results
3.3.1 Accuracy on phantom dataset
Table 3.1 presents the quantitative results of Ace concentration ratio between
cylinders 5 and 2, and 7 and 3 respectively, both at low resolution (acquired
at 10×10×10 mm3) and at high-resolution (reconstructed at 1.25×1.25×1.25
mm3) for all methods. On average, PBSR and LIN seem to preserve better
median metabolite ratio compared to other methods. However, the visual
assessment for all methods (figure 3.2) shows that contrary to conventional
interpolation methods, PBSR reduced the partial volume effects considerably
by incorporating tissue segmentation information. Therefore, overall PBSR
provides better results.
3.3.2 Accuracy on simulated brain datasets
Figures 3.3, 3.4 and 3.5 show the respective visual results for all methods on
mild, moderate and severe MS subjects. On close inspection, it can be seen
that PBSR maintains better tissue contrast compared to other methods. For
PBSR, this contrast is also more evident between lesions and their surrounding
white matter, both visually and quantitatively (see table 3.2). Moreover, the
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Figure 3.2: High-resolution Ace maps comparison for all methods. (a) Schematic
representation of the phantom arrangement, (b) acquired low resolution Ace map.
Reconstructed high-resolution Ace map for (c) patch-based super-resolution, (d) nearest
neighbour, (e) linear interpolation, and (f) B-splines.
Table 3.1: Comparison between Ace concentration at low resolution (10×10×10 mm3) and
high-resolution (1.25×1.25×1.25 mm3). Cylinders 5 and 7 have twice the Ace concentration
of cylinders 2 and 3, respectively.
Ace ratio (median) cylinder 5cylinder 2
cylinder 7
cylinder 3
Low resolution 2.33 1.80
High-resolution
PBSR 1.86 1.89
NN 2.25 1.6
LIN 1.75 2.0
BS 1.83 1.75
PBSR = patch-based super-resolution, NN = nearest neighbour, LIN = linear interpolation, BS = B-splines.
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Figure 3.3: Results on simulated mild MS subject. (a) Bias corrected FLAIR image
followed by (b) overlaid lesion segmentation, (c) simulated low resolution NAA map, (d-h)
the high-resolution NAA maps: (d) simulated, (e) patch-based super-resolution, (f) nearest
neighbour, (g) linear interpolation and (h) B-splines. The NAA concentration increases from
red to blue.
median value in white matter surrounding lesions for PBSR is closest to the
actual value considered for WM, 25, compared to other methods. For lesions,
the median value for all methods is close to 20 with slightly better effect size
for PBSR. SSIM score for all methods is very high with PBSR being marginally
higher.
3.3.3 Accuracy on human datasets acquired in vivo
Figures 3.6 and 3.7 show the high-resolution NAA and myo-Ins maps respectively,
for all methods on a representative example. In contrast to the results on the
simulated brain datasets, visually it is very difficult to see a correlation between
any method and the acquired high-resolution maps. However, quantitatively, a
contrast between lesions and surrounding white matter can be computed (table
3.3). The acquired high-resolution shows a significant contrast between lesions
and their surrounding WM, which is not seen at acquired low resolution. For
NAA, this significant contrast can only be seen in PBSR. For myo-Ins, this
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Figure 3.4: Results on simulated moderate MS subject. (a) Bias corrected FLAIR image
followed by (b) overlaid lesion segmentation, (c) simulated low resolution NAA map, (d-h)
the high-resolution NAA maps: (d) simulated, (e) patch-based super-resolution, (f) nearest
neighbour, (g) linear interpolation and (h) B-splines. The NAA concentration increases from
red to blue.
significant contrast is highest for LIN followed by BS, NN and PBSR. The
average SSIM score is highest for PBSR for both NAA and myo-Ins compared
to the other methods, which have equal average SSIM scores.
3.4 Discussion and conclusions
In this chapter, we presented a patch-based super-resolution method for
upsampling the low resolution quantified metabolite maps. The method
incorporates the high-resolution spatial information from T1-weighted and
FLAIR MR images in guiding the reconstruction process. The method iteratively
estimates and corrects for the metabolite concentration at a high-resolution. In
contrast to the k-space based techniques where anatomically derived information
is used to improve the spectral quality of high-resolution MRSI data, in our
case, the method reconstructs each central voxel xi using a weighted average of
voxels that have similar tissue composition as the central voxel in the search
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Figure 3.5: Results on simulated severe MS subject. (a) Bias corrected FLAIR image
followed by (b) overlaid lesion segmentation, (c) simulated low resolution NAA map, (d-h)
the high-resolution NAA maps: (d) simulated, (e) patch-based super-resolution, (f) nearest
neighbour, (g) linear interpolation and (h) B-splines. The NAA concentration increases from
red to blue.
volume. Moreover, as MRI and MRSI have complementary information, separate
weights are defined for each modality which are regulated with a parameter
α(xi). Depending on the application, α(xi) gives the flexibility to control the
influence of each modality in the reconstruction process. In this chapter, when
α(xi) = 1, the reconstruction is guided by MRSI only resulting in a smooth
image and when α(xi) = 0, the reconstruction is guided by MRI alone resulting
in a better tissue contrast compared to conventional interpolation techniques
(see tables 3.2 and 3.3). The reconstruction quality is affected by the potential
registration errors and the reliability of the input quantified metabolite map.
Additionally, the method could not be expected to recover small scale features
that were not sufficiently picked up by the low resolution measurement. On
a similar note, the use of tissue segmentations to guide the reconstruction
might affect metabolite values at tissue interfaces. In particular, through such
an effect, some hyper intense voxels are introduced near the brain boundary,
requiring further investigation. Finally, if the difference between the image
resolution of MRI and MRSI images is big (scale factor more than 4), then the
downsampled tissue segmentations for super-resolution process have high partial
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Table 3.2: Quantitative measures for measuring the accuracy of all methods on simulated
brain datasets.
Mild
NWMNAA LesionsNAA p-value effect size SSIM
PBSR 25.26 (24.93, 25.62) 20.34 (19.33, 22.72) 3.07 e-08 2.9 0.93
NN 24.06 (23.7, 24.11) 20.07 (18.86, 21.02) 1.65 e-06 2.12 0.93
LIN 23.75 (22.83, 24.27) 20.46 (19.94, 21.7) 2.39 e-07 2.31 0.92
BS 23.7 (22.5, 24.45) 20.07 (19.2, 21.02) 7.20 e-07 2.18 0.92
Moderate
PBSR 25.26 (23.75, 25.5) 20.38 (19.56, 22.09) 1.61 e-18 1.11 0.93
NN 23.67 (21.65, 24.99) 20.1 (19.41, 21.65) 4.71 e-19 1.08 0.92
LIN 23.11 (21.04, 24.33) 20.37 (19.6, 21.66) 2.48 e-12 0.83 0.92
BS 23.37 (20.94, 24.5) 20.25 (19.53, 21.7) 8.43 e-14 0.89 0.92
Severe
PBSR 25.13 (22.12, 25.49) 20.47 (19.7, 21.66) 2.5 e-41 1.21 0.93
NN 22.98 (20.34, 24.83) 20.18 (19.75, 21.39) 9.54 e-36 1.11 0.92
LIN 22.94 (20.55, 24.35) 20.48 (19.77, 21.4) 1.2 e-32 1.04 0.92
BS 22.86 (20.56, 24.54) 20.28 (19.6, 21.11) 1.38 e-34 1.08 0.92
NWMNAA = NAA concentration in white matter surrounding lesions,
LesionsNAA = NAA concentration in lesions,
PBSR = patch-based super-resolution, NN = nearest neighbour, LIN = linear interpolation, BS = B-splines,
p-value = Welsh’s t-test p-value for testing the statistical difference between NWMNAA and LesionsNAA,
effect size = the magnitude of statistical difference, SSIM = structural similarity index.
NWMNAA and LesionsNAA are reported as median (first quartile - third quartile).
volume effect and thus do not carry much information on tissue type. That is
why in this study, we limited the in-plane resolution of acquired low resolution
MRSI to ∼ 3.4×3.4 mm2. Our method can also be implemented in a multi-scale
fashion. However, validating such high-resolution reconstructed image would
be a problem in case of real datasets (e.g., human datasets acquired in vivo)
where acquiring such high-resolution image is not possible due to practical
limitations. Indeed, multi-scale super-resolution method can easily be tested on
a simulated data, and, as our results show better tissue contrast at the current
high-resolution, we expect similar or better results at even higher resolution.
Our main aim in this chapter was to validate the method on real datasets and
thus we opted not to use the multi-scale super-resolution.
Among the methods proposed in the literature for super-resolution, our approach
has some similarities to [135], which is also based on patch-based framework.
In contrast with [135], which uses a neighbourhood averaging strategy to define
MRI weights, we used brain tissue segmentations. In [135], α(xi) defines the
correlation between high-resolution and low resolution images and is adapted in
each iteration. In our case, α(xi) is defined using binarised lesion segmentation
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Figure 3.6: Qualitative accuracy performance of all methods on human dataset acquired in
vivo for NAA metabolite. (a) Bias corrected FLAIR image followed by (b) overlaid lesion
segmentation, (c) the acquired low resolution NAA map; (d-h) the high-resolution NAA maps:
(d) acquired, (e) patch-based super-resolution, (f) nearest neighbour, (g) linear interpolation
and (h) B-splines. The NAA concentration increases from red to blue.
and is fixed throughout the process.
One of the biggest problems that we encountered in this study was having ideal
data for method validation. Challenges include (a) absence of high-resolution
ground truth data, (b) lack of a publicly available dataset, and (c) difference
between low and high-resolution acquired MRSI data. Acquiring high-resolution
ground truth data in reality is not feasible because low metabolite concentration
requires large voxel size to capture sufficient signal, and prolonged acquisition
time. Although several group studies have reported metabolite concentration
in normal and pathological cases like MS [139, 18], conclusions are not easily
generalisable when it comes to individual patients. Lack of a standardised
acquisition protocol for high spatial resolution MRSI hampers the creation of
publicly available datasets against which state-of-the-art methods’ performances
can be compared. Moreover, most of the state-of-the-art super-resolution
methods for MRSI improve MRSI data using sophisticated reconstruction
techniques (k-space based), which make their reproducibility for comparison
very difficult. However, from a methodological point of view, our method requires
fewer variables to be optimised simultaneously which simplify the underlying
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Figure 3.7: Qualitative accuracy performance of all methods on human dataset acquired
in vivo for myo-Ins metabolite. (a) Bias corrected FLAIR image followed by (b) overlaid
lesion segmentation, (c) the acquired low resolution myo-Ins map; (d-h) the high-resolution
myo-Ins maps: (d) acquired, (e) patch-based super-resolution, (f) nearest neighbour, (g) linear
interpolation and (h) B-splines. The myo-Ins concentration increases from red to blue.
optimisation problem. For example, in k-space based methods, the MRI spatial
parameters (e.g., bias field inhomogeneity, tissue class information) and the
MRSI spectral parameters (e.g., metabolite amplitudes, B0 shifts, zero-order
phase and lineshape parameters) have to be optimised simultaneously, which
may result in a sub-optimal solution. In our case, we deal with the MRI spatial
parameters and MRSI spectral parameters separately. Bias field correction and
tissue class segmentation are performed by MSmetrix (3.2.1) and the interaction
between neighbourhood voxels is exploited in the proposed super-resolution
method. The spectral parameters are estimated by state-of-the-art metabolite
quantification methods such as LCModel or SPID.
In human MRSI data acquired in vivo, the median metabolite concentrations
acquired at low resolution are greater than those at higher resolution (see table
3.3), although the same quantification method (LCModel) and parameters have
been used to quantify metabolic maps at both resolutions. This generates a
degree of uncertainty in the interpretation of the performance analysis. This issue
was not present in the simulated data, which explains a significant decrease
in the SSIM score from simulated brain datasets’ (see table 3.2) to human
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Table 3.3: Accuracy results on human datasets acquired in vivo.
NAA
NWMNAA LesionsNAA p-value effect size aSSIM
ALR 15.18 (14.47, 16.87) 15.62 (13.39, 18.02) 0.8 -0.07 NA
AHR 13.41 (12.48, 15.0) 12.99 (10.99, 14.85) 0.03 0.31 NA
PBSR 16.85 (15.99, 17.6) 15.6 (13.82, 17.27) 2.0 e-05 0.64 0.18
NN 16.23 (14.82, 17.34) 15.75 (13.62, 17.61) 0.35 0.14 0.13
LIN 16.1 (14.93, 17.26) 15.71 (13.85, 17.35) 0.38 0.13 0.13
BS 16.15 (14.79, 17.33) 15.49 (13.64, 17.5) 0.3 0.15 0.13
myo-Ins
ALR 10.8 (10.09, 12.69) 11.88 (10.9, 14.48) 5.0 e-02 -0.57 NA
AHR 6.03 (4.78, 7.86) 11.48 (9.13, 13.15) 4.3 e-16 -1.63 NA
PBSR 8.07 (6.78, 9.39) 10.59 (9.89, 11.79) 3.0 e-08 -1.04 0.2
NN 9.17 (7.77, 9.98) 11.97 (10.5, 13.35) 1.9 e-09 -1.15 0.18
LIN 9.11 (7.89, 10.11) 11.98 (10.82, 13.25) 4.7 e-11 -1.27 0.18
BS 9.12 (7.86, 10.15) 11.88 (10.72, 13.35) 1.2 e-10 -1.23 0.18
NWMNAA = NAA concentration in white matter surrounding lesions,
LesionsNAA = NAA concentration in lesions,
PBSR = patch-based super-resolution, NN = nearest neighbour, LIN = linear interpolation, BS = B-splines,
p-value = Welsh’s t-test p-value for testing the statistical difference between NWMNAA and LesionsNAA,
effect size = the magnitude of statistical difference, aSSIM = averaged structural similarity index over 5 subjects.
NWMNAA and LesionsNAA are reported as median (first quartile - third quartile).
ALR = acquired low resolution map, AHR = acquired high-resolution map.
datasets’ acquired in vivo (see table 3.3). This decrease can also be explained
by the fact that simulated low resolution MRSI data has twice the resolution
of low resolution MRSI human datasets acquired in vivo, resulting in a loss of
structural information. Finally, it may seem like the conventional interpolation
methods provide better results than PBSR for myo-Ins (see table 3.3), however
this is not completely true. Four out of five MS subjects in the human datasets
acquired in vivo, have low lesion load in the acquired MRSI plane and the
remaining subject has high lesion load. If this subject is removed, none of
the methods show any statistical difference in the metabolite concentrations
between the lesions and their neighbouring WM tissue for myo-Ins. However,
this statistical difference still holds true for NAA. Tuning the parameter α(xi)
may address this issue.
In conclusion, we presented a patch-based super-resolution approach for
upsampling the low resolution quantified metabolites maps using T1-weighted
and FLAIR MR images. The proposed method preserves tissue contrast and
structural information compared to conventional interpolation methods, and
matches well with the trend of acquired high-resolution MRSI. These results
suggest that the method has potential for clinically relevant neuroimaging
applications.
Chapter 4
Two time points MS lesion
segmentation
Abstract
Consistent MS lesion segmentation is important for monitoring of disease activity
in a follow-up scan, where differences are clinically relevant. In this chapter,
we present MSmetrix-long: a joint EM framework for two time point white
matter lesion segmentation. MSmetrix-long takes as input a 3D T1-weighted
and a 3D FLAIR MR image and segments lesions in three steps: (1) cross-
sectional lesion segmentation of the two time points; (2) creation of difference
image, which is used to model the lesion evolution; (3) a joint EM lesion
segmentation framework that uses the output of step (1) and step (2) to provide
the final lesion segmentation. MSmetrix-long outperfoms MSmetrix-cross in
terms of accuracy and consistency in segmenting MS lesions. Also, MSmetrix-
long compares favourably with the publicly available longitudinal MS lesion
segmentation algorithm of Lesion Segmentation Toolbox.
4.1 Introduction
Accurate and reliable lesion segmentation based on brain MRI scans is valuable
for the diagnosis and monitoring of disease activity in patients with MS [17,
The work presented in this chapter has been published in: Jain, S., Ribbens, A., Sima, D.M., Cambron, M.,
De Keyser, J., Wang, C., Barnett, M.H., Van Huffel, S., Maes, F. and Smeets, D. Two Time Point MS Lesion
Segmentation in Brain MRI: An Expectation-Maximization Framework. Frontiers in Neuroscience 10: 576 (2016), 11
pages.
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Figure 4.1: Bias corrected FLAIR images (a, e) followed by super-imposed lesion
segmentations from: (b, f) the expert, (c) disappearing lesion, (d) shrinking lesion, (g)
new lesion, and (h) enlarging lesion. The first row corresponds to time point 1 and the second
row corresponds to time point 2.
41]. The availability of longitudinal MRI data permits an analysis of lesion
evolution over time, a potential biomarker of disease progression and treatment
efficacy. Figure 4.1 shows bias corrected FLAIR images of a MS subject scanned
twice with an interval of approximately one year, along with the expert lesion
segmentation followed by the lesion evolution i.e., the new, disappearing,
enlarging and shrinking lesions. Although expert manual delineation of lesions
is considered as the gold standard, it is time consuming and often suffers
from intra and inter observer variability [3]. To alleviate this problem, several
automatic methods have been proposed in the literature to segment MS lesions.
Interestingly, the vast majority of automatic methods are based on a single time
point (cross-sectional) and relatively few methods take into account multiple
time points (longitudinal) [61, 101]. Executing a cross-sectional method for
each time point would indeed produce the longitudinal measures of interest, but
such measures are less reliable as each time point is processed independently.
Longitudinal methods incorporate both spatial and temporal information and
are expected to be more reliable. Based on the underlying approach, longitudinal
methods could be categorised in three different groups: change detection [20,
48, 124, 165, 130], 4D connectivity [14, 172] and outlier detection [2, 154] in
multiple time points. Pre-processing of input MR images in these three groups
is generally performed and consists of registration to a reference image or a
common space, skull stripping, bias field correction and intensity normalisation.
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Change detection methods primarily aim to detect MS activity by statistical
analysis of image features or by measuring local volume variation. Statistical
analysis can be performed in an unsupervised or supervised manner. Unsuper-
vised approaches detect significant changes in the intensities between consecutive
scans by either analysing the corresponding patches of two time points [20],
or performing clustering on the extracted spatial and temporal features from
longitudinal images [64, 124, 165]. The main drawback with unsupervised
approaches is that they assume perfect registration and intensity normalisation.
Supervised approaches learn the desired change from a training dataset; for
instance, in [48], a random forest discriminative classifier was trained to learn
relevant features (intensity, size and contextual information) related to new
lesions and then use these features to segment them. The main drawback with
this approach is that it often requires that the training dataset is large enough
in order to capture all the distinctive features of the lesions to be segmented.
To avoid the need for extracting image features, changes between consecutive
images could be directly detected by measuring local volume variations. To
this end, a Jacobian operator could be applied to the local deformation field
obtained after non-rigid registration between the two time points. Although
this approach has proven to be invariant to registration errors, it has given poor
results for lesion segmentation [130].
Four-dimensional connectivity methods use voxel association in space and time to
simultaneously segment and track lesion evolution. For example, [172] segments
the lesions in two time points by clustering voxels that are both spatially and
temporally adjacent to each other. The main disadvantage of this approach is
that it often results in substantial false lesion segmentation. A more advanced
method from the same family is based on spectral graph partitioning [14]. It
constructs a 3D graph in which spatial pairwise affinities characterise lesions
and background, and temporal affinities between adjacent time points represent
lesion evolution direction. This graph is segmented into lesions and non-lesions
via spectral clustering by maximising the force within-group attraction and
between-group repulsion. The drawback of this approach is that it cannot
discriminate between consistent artefacts and lesions.
Outlier detection methods are based on the fact that MS lesions are hyper-
intense on T2-weighted and FLAIR brain MRI scans and thus could be detected
as an outlier to normal tissue class intensities distribution. For example, a joint
EM based approach such as in [2] models the healthy brain tissue classes across
the time points as a Gaussian mixture model (GMM) using a 4D (3D + time)
intensity histogram. The parameters of the model are optimised via a modified
version of the EM algorithm referred to as STREAM. After convergence, the
lesions are extracted as outliers to healthy tissue classes using Mahalanobis
distance and some prior information. In this approach the lesion segmentation is
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largely dependent on the choice of the Mahalanobis distance parameter and does
not target lesion evolution, which is clinically relevant [2]. Another approach
using outlier detection is based on the hidden Markov model (HMM) technique
as in [154]. Initially, EM segments the first time point into different tissue
classes including lesions, which are then manually corrected. Subsequently, using
a lesion growth transition model and outlier detection sensor model, lesions
are segmented in the following time points. The transition model enforces
consistent lesion segmentation; however, it was validated only on simulations
with exponential lesion growth.
In this chapter, we present MSmetrix-long: an iterative white matter lesion
segmentation method based on a joint EM framework that takes as input
clinically acquired 3D T1-weighted and 3D FLAIR images of two time points.
The proposed framework is fully automated, unsupervised and models the
lesion evolution as GMM between two time points, thereby simultaneously
segmenting new, enlarging, disappearing, shrinking and static lesions. The
method is validated for accuracy and reproducibility on two different datasets
that are representative for clinically feasible acquisition protocols.
4.2 Methods
4.2.1 Method description
The MSmetrix-long pipeline analyses the MS lesions evolution between two
time points based on 3D T1-weighted and 3D FLAIR image acquired at each
time point. The pipeline has four steps:
1. cross-sectional analysis, that segments the individual time points into GM,
WM, CSF and lesions.
2. FLAIR based difference image, which is created by subtracting the FLAIR
images of both time points after bias correction, co-registration and
intensity normalisation.
3. joint lesion segmentation, that aims to improve the individual time point
lesion segmentation using the other time point information on tissue and
lesion segmentation (initialised using step-1 results) and difference image
obtained from step-2.
4. a pruning step, that refines the lesion segmentation obtained in the step-3
to eliminate non-lesion candidates.
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Figure 4.2: An illustrative example explaining the different steps of our method. The pink
arrows in the longitudinal lesion segmentation at time point 1 show the recovered lesions
using the second time point lesion segmentation and difference image information.
Figure 4.2 presents an illustrative explanation of these steps. Steps (3) and
(4) are performed sequentially in both directions, by using one time point as
reference and then the other. These steps are also iterated, by changing the
input lesion segmentation used as prior. Only for the first iteration, the lesion
segmentations priors come from the cross-sectional pipeline in step-3, while from
the second iteration onwards lesion segmentations from previous iteration are
used to initialise the lesion priors for the current iteration. The convergence of
our method is decided when the relative lesion segmentation difference between
the current and previous iteration is negligible. It takes generally three iterations
for the algorithm to converge. The following sections explain the different steps
in more detail.
Cross-sectional analysis
Image segmentation is performed independently for each time point using the
cross-sectional pipeline referred to as MSmetrix-cross (see chapter 2). The
cross-sectional method iteratively segments the T1-weighted image into GM,
WM and CSF, segments the WM lesions on the FLAIR image as an outlier
to normal brain using Mahalanobis distance, and performs lesion filling in the
T1-weighted image to improve tissue segmentation at next iteration. After
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convergence, segmentations of WM, GM, CSF and lesions are created. In
addition, bias corrected T1-weighted and FLAIR images are also produced.
The segmentation tasks of the MSmetrix-cross are optimised using an EM
algorithm [177] as implemented in NiftySeg [26].
FLAIR based difference image
A FLAIR based difference image is created by image co-registration and intensity
normalisation. Image co-registration is performed using affine registration, which
comprises a rigid registration based on the whole T1-weighted image, followed
by a skull based affine registration to avoid small scaling differences, and a final
whole brain rigid registration [151]. The rigid registration and skull based affine
registration use an inverse consistent registration algorithm [107]. Subsequently,
the GM, WM, CSF, lesion segmentation and the bias corrected FLAIR images
obtained from the cross-sectional analysis are propagated using the final affine
transformation. The matched bias corrected FLAIR images are then corrected
for differential bias field as described in [98]. Subsequently, the differential bias
field corrected images are intensity normalised using a cumulative histogram
matching technique [27] with the image of time point 1 as reference. A FLAIR
based difference image is now created in time point 1 space. To avoid bias
towards a specific time point, a second difference image is created, using time
point 2 space as reference.
Joint lesion segmentation
We now define a model that aims at joint tissue class label segmentation of the
images of both time points (see the blocks denoted by ‘Joint lesion segmentation’
in figure 4.2). The observed variables for the model are FLAIR image intensities
of both time points as well as the corresponding FLAIR based difference image.
The hidden variables for the model are tissue class labels for which prior
knowledge is initially provided in the form of tissue class segmentations from
MSmetrix-cross. Optimisation of the model results in a lesion segmentation at
each time point that is based on information from both images. As mentioned
above, to avoid a bias towards a specific time point, the joint lesion segmentation
is performed separately in both directions. We now describe the notations,
variables and assumptions used, followed by the model definition.
Notations, variables and model assumptions
We assume that image 1, image 2 and difference image are co-registered and
have the same number of voxels, NJ . Let I1= {y(1)j | j ∈ {1, .., NJ}}, I2= {y(2)j
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| j ∈ {1, .., NJ}} and D = {y(D)j | j ∈ {1, .., NJ}} be the set of image intensities
with y(1)j , y
(2)
j and y
(D)
j being the intensities corresponding to voxel j in image
1, image 2, and difference image respectively.
We assume identical tissue classes in both images and their total number
denoted by NK . Let k = {1, .., NK} be the set of tissue classes with k(1) and
k(2) denoting a tissue class index for image 1 and image 2, respectively such
that k(1) and k(2) ∈ {1, .., NK}. The tissue class label in image 1 is defined
as: L1= {l(1)j,k(1) | j∈{1, .., NJ}, k(1) ∈ {1, .., NK}}; l
(1)
j,k(1)
is 1 if voxel j has
tissue class label k(1) in I1, 0 otherwise; l(1)j,k(1) is subjected to the constraint:∑
k(1)
l
(1)
j,k(1)
= 1. Similarly, the set of tissue class labels in image 2 are denoted by
L2 and defined in the same way as for L1.
We now specify our model assumptions. A Gaussian mixture model is used on
the image intensities of each time point where a Gaussian model is used for
each tissue class k. Let {µ(1)
k(1)
, σ2(1)
k(1)
} be the mean and variance of Gaussian
model parameters for tissue class k(1) and let θ1 denote the Gaussian mixture
model parameters for the intensities of image 1. The probabilistic model for
image 1 can be defined as:
P (I1|L1, θ1) =
∏
j,k(1)
N
(
y
(1)
j |µ(1)k(1) , σ
2(1)
k(1)
)l(1)
j,k(1) (4.1)
Analogously, the probabilistic model for image 2 can be defined as:
P (I2|L2, θ2) =
∏
j,k(2)
N
(
y
(2)
j |µ(2)k(2) , σ
2(2)
k(2)
)l(2)
j,k(2) (4.2)
We make the underlying assumption that the ‘difference image’ might be
independently generated as an image that captures anatomical changes including
new lesions or atrophy. The image created by subtracting image 1 from
image 2 or vice-versa (after intensity normalisation) is one such instance of the
difference image. The intensity model of image 1 and image 2 can therefore be
improved by including a transition model defined on the difference image. As
our method focuses on two time points WM lesion segmentation, we only model
the transformations between WM and lesions. We assume that the difference
image has three different transformations: ‘static’, ‘growth’ and ‘shrinkage’.
The static transformation class is defined as a set of voxels in the difference
image that are either labeled as WM in both images or lesions. The growth
transformation class (describing the new and enlarging lesions) is defined as a set
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Figure 4.3: (a) Normalised FLAIR image of time point 1, (b) FLAIR image of time point
2, (c) difference image (b-a), (d) histograms of difference image classes with corresponding
Gaussian fitting, normalised per class. Note the artifactual difference values at the brain
contour (due to subtle differences in brain mask extraction) are excluded by only including
WM voxels in the analysis.
of voxels in the difference image that are labelled as WM in image 1 and lesion
in image 2. The shrinkage transformation class (describing the disappearing
and shrinking lesions) is defined as a set of voxels in the difference image that
are labelled as lesion in image 1 and WM in image 2. For all other possible
tissue transformations from image 1 and image 2 a uniform distribution is
assumed. Figure 4.3 shows an illustrative example of the difference image and
the histograms of its classes with corresponding Gaussian fitting.
Under these assumptions, a Gaussian mixture model for the difference image
intensities is used where each transformation class is modelled as Gaussian:
P (D|L1, L2, ζ) =

∏
j,k(1),k(2)
N
(
y
(D)
j |µ(D)k(1),k(2) , σ
2(D)
k(1),k(2)
)l(1)
j,k(1)
, l
(2)
j,k(2) ,with k(1) and k(2) ∈ {WM, lesion}
∝ 1 ,∀ other k(1) and k(2) combinations.
(4.3)
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where the parameter ζ = {θstatic, θgrowth, θshrinkage} with
θstatic = {µ(D)static, σ2(D)static}, if
{
k(1) = k(2) = WM or
k(1) = k(2) = lesion
(4.4)
θgrowth = {µ(D)growth, σ2(D)growth}, if
{
k(1) = WM and
k(2) = lesion
(4.5)
θshrinkage = {µ(D)shrinkage, σ2(D)shrinkage}, if
{
k(1) = lesion and
k(2) = WM
(4.6)
Finally, we assume that we have no prior knowledge on the relationship of
the tissue class labels between both images which is generally provided by a
probabilistic atlas. Therefore, we define the prior probabilities independently
for each image using the tissue class segmentations from our cross-sectional
model. The prior probabilities on tissue class labels for the image 1 and image
2 are denoted by P (L1) and P (L2), and are defined as:
P (L1) =
∏
j,k(1)
(
α
(1)
j,k(1)
)l(1)
j,k(1) , P(L2) =
∏
j,k(2)
(
α
(2)
j,k(2)
)l(2)
j,k(2) (4.7)
where α(1)
j,k(1)
and α(2)
j,k(2)
are the tissue class segmentations of image 1 and image
2 respectively. For the first iteration of joint lesion segmentation, these tissue
class segmentations comes from the cross-sectional method. From the second
iteration, the obtained lesion segmentations from previous iteration are used to
initialise the lesion priors for current iteration.
The model
Under these assumptions, the joint probabilistic model could be formulated as
follows:
P (I1, I2, D, L1, L2, γ) = P (I1|L1, θ1). P (I2|L2, θ2). P (D|L1, L2, ζ). P (L1). P (L2) (4.8)
where γ = {θ1, θ2, ζ}. Our model is optimised by the maximum a posteriori
(MAP) problem shown in equation 4.9. Since the knowledge of tissue class
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labels (hidden variables) helps in finding the model parameters and vice-versa,
we reformulate our MAP problem as presented in equation 4.10.
γˆMAP = argmax
γ
ln P (γ|I1, I2, D) = argmax
γ
ln P (I1, I2, D, γ) (4.9)
= argmax
γ
ln
∑
L1,L2
P (I1, I2, D, L1, L2, γ) (4.10)
≥ argmax
γ
∑
L1,L2
P (L1, L2|I1, I2, D, γ) ln P (I1,I2,D,L1,L2,γ)P (L1,L2|I1,I2,D,γ) (4.11)
Finally, a lower bound of our model is derived using Jensen’s inequality and
optimised by the EM algorithm. The Q-function or the E-step can now be
written as:
Q(γ|γ) = EL1,L2|I1,I2,D,γ [ ln P (I1, I2, D, L1, L2, γ)] (4.12)
with the joint posterior distribution P (L1, L2|I1, I2, D, γ), which can be
formulated in every voxel j for tissue class k(1) and k(2) as:
pj,k(1),k(2) =
p(y(1)j , y
(2)
j , y
(D)
j , l
(1)
j,k(1)
= 1, l(2)
j,k(2)
= 1, γ)∑
k(1),k(2)
p(y(1)j , y
(2)
j , y
(D)
j , l
(1)
j,k(1)
, l
(2)
j,k(2)
, γ)
(4.13)
The sum over all possible tissue classes k(2) of the joint posterior gives us the
soft tissue class segmentations at time point 1, referred to as pj,k(1) . Similarly,
the sum over all possible tissue classes k(1) of the joint posterior gives us the
soft tissue class segmentations at time point 2, referred to as pj,k(2) .
pj,k(1) =
∑
k(2)
pj,k(1),k(2) (4.14)
pj,k(2) =
∑
k(1)
pj,k(1),k(2) (4.15)
In the M-step, a new set of values for model parameter γ is computed by
maximising the Q-function. For the Gaussian parameters of the tissue class k(1)
we find:
µ
(1)
k(1)
=
∑
j
pj,k(1)y
(1)
j∑
j
pj,k(1)
(4.16)
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σ
2(1)
k(1)
=
∑
j
pj,k(1)
[
y
(1)
j − µ(1)k(1)
]2
∑
j
pj,k(1)
(4.17)
In a similar way, the Gaussian parameters of the tissue class k(2) {µ(2)
k(2)
, σ2(2)
k(2)
}
could be derived.
For the difference image parameter ζ = {µ(D)
k(1),k(2)
, σ
2(D)
k(1),k(2)
} = {(µ(D)static, σ2(D)static),
(µ(D)growth, σ
2(D)
growth), (µ
(D)
shrinkage, σ
2(D)
shrinkage)}, the general form of mean and
variance for every transformation class can be written as:
µ
(D)
k(1),k(2)
=
pj,k(1),k(2) y
(D)
j∑
j
pj,k(1),k(2)
(4.18)
σ
2(D)
k(1),k(2)
=
pj,k(1),k(2)
[
y
(D)
j − µ(D)k(1),k(2)
]2
∑
j
pj,k(1),k(2)
(4.19)
where k(1) and k(2) ∈ {WM, lesion} and depending on the k(1) and k(2)
combination as mentioned in equations-[4.4, 4.5, 4.6] mean and variance of each
transformation class can be derived.
Pruning
The soft lesion segmentations obtained from the E-step of the joint EM algorithm
are pruned to eliminate non-lesions (such as partial volume effects, artefacts)
that share intensities and locations with the potential lesions. Thereto, a priori
information on the appearance, location and volume of lesions is incorporated:
(1) the lesion intensities should be hyper-intense compared to the WM intensities
on bias field corrected FLAIR image, (2) the lesions are in the WM region, and
(3) the lesion needs to have a minimum number of 5 adjacent voxels (empirically
determined) to avoid spurious lesion detection. The hyper-intensity is defined
as the mean plus two times the standard deviation of WM intensities. The
intensities and location of WM region are computed using the WM segmentation
from the MSmetrix-cross pipeline. In addition, a priori defined binary mask
(defined in the MNI space and consisting of the cerebral cortex and WM in-
between the ventricles) is warped to the subject space to remove lesion candidates
from these regions that are likely to result in a false lesion segmentation. After
the pruning, the soft lesion segmentations are binarised using a threshold of 0.9
(empirically determined) on the posterior probabilities.
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4.2.2 Comparison with state-of-the-art methods
We compare MSmetrix-long pipeline1 with the MSmetrix-cross pipeline to
know the gain over the cross-sectional method. Furthermore, we also compare
against the longitudinal pipeline of the LST software package [142], version
2.0.12, which is implemented in SPM122. The longitudinal pipeline of LST,
which is referred to as LST-long in this chapter, performs individual time point
lesion segmentation using the lesion growth algorithm described in [142]. The
obtained lesion segmentation maps of different time points are coregistered to
the baseline scan and are corrected by comparing the relative differences of
FLAIR intensities in all lesion maps to produce the final lesion segmentation at
each time point (see LST documentation3).
For comparison, all three methods were executed on the same datasets and
default parameter settings were used. Thus, no parameter tuning was performed
at dataset or subject level.
4.2.3 Data
Dataset 1 contains scans from 12 relapsing remitting MS patients on a GE 3T
scanner (Discovery MR750), each scanned twice at an interval of approximately
one year. Therefore, the sample size of dataset 1 equals 24. Each time point
contained two a 3D sequences: a CUBE FLAIR (TR: 8000 ms, TE: 165 ms, TI:
2179 ms) and a 3D T1-weighted IR-FSPGR sequence (TR 7.2 ms, TE 450 ms,
TI 2.8 ms). Both 3D sequences have voxel resolution close to 1 mm3. Expert
WM lesion segmentations were created on the baseline FLAIR scan by the
experienced neuro-imaging analyst using JIM software tool4, version 6.0. For
follow-up scans, baseline lesion segmentation was overlaid on rigidly registered
follow-up scan at the beginning, and then the lesion segmentation was adapted
according to lesion activities. This study was reviewed and conducted within
the guidelines set out in the National Statement on Ethical Conduct in Human
Research (2007) in Australia, and approved by University of Sydney Human
Research Ethics Committee. All subjects gave written informed consent.
The second dataset, dataset 2 contains scans from 10 MS patients scanned
twice, with re-positioning (time interval between two scans is 5 ∼10 minutes),
on each of three different 3T scanners from GE (Discovery MR750w), SIEMENS
1MSmetrix-long pipeline presented here is the version 1.4 of the clinical product –
MSmetrix.
2http://www.fil.ion.ucl.ac.uk/spm/software/spm12/
3LST,www.statistical-modelling.de/lst.html
4JIM,http://www.xinapse.com
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(Skyra) and PHILIPS (Achieva). This dataset is the same as the dataset 2 used
in chapter 2, section 2.2.3, table 2.1.
4.2.4 Performance tests
Accuracy and reproducibility assessment
The agreement between the expert segmentation and automatic methods on
dataset 1 is evaluated at three levels: voxel-by-voxel, lesion-wise and volumetric.
Voxel-by-voxel metric includes the Dice similarity index. The lesion-wise metrics
include lesion-wise true positive rate, false positive rate, F1 score, absolute
lesion change difference and Pearson correlation coefficient (r value). Lesion-wise
true positive rate (LTPR) is defined as the ratio of the total number of lesions
where the expert reference and the automatic segmentation intersect to the
total number of lesions in the expert reference segmentation. Lesion-wise false
positive rate (LFPR) is defined as the ratio of the total number of lesions that
are present only in the automatic segmentation to the total number of lesions
in the automatic segmentation. Lesion-wise F1 score is defined as the harmonic
mean of LTPR and LFPR. Absolute lesion-wise change difference is defined as
the absolute difference between the overall lesion-wise change (number of new
lesions minus number of disappearing lesions) in the expert lesion segmentation
and the automatic segmentation. In this chapter, we consider new, disappearing,
enlarging and shirking lesions that have size more than 20 voxels and at least
one slice which encompasses the lesion presents a minimum of 5 lesion voxels.
Volumetric metrics measure the total lesion volume agreement and consist of
the r value and the absolute volume difference. The absolute volume difference
is computed as the absolute difference between the total volume reported by
the expert reference segmentation and the corresponding value derived from
the automatic method.
The reproducibility of the method is evaluated on dataset 2 by the Dice similarity
index of the lesion segmentations at both times points. Moreover, the estimated
number of new lesions and the absolute total lesion volume difference is also
calculated between time points, which are both expected to be zero in this
test-retest scenario.
To determine if there is a statistical difference between MSmetrix-long and LST-
long and between MSmetrix-cross and MSmetrix-long methods’ performance,
two tailed paired Wilcoxon signed-rank test is performed.
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Figure 4.4: Bias corrected FLAIR image (a) followed by super-imposed lesion segmentation
from: (b) expert segmentation, (c) MSmetrix-cross, (d) MSmetrix-long, and (e) LST-long.
The first row corresponds to the lesion segmentation of time point 1 and the second row
corresponds to the lesion segmentation of time point 2. Pink arrows specify places where
MSmetrix-long has improved in accuracy over MSmetrix-cross and red arrows indicate
regions where LST-long has missed lesions.
4.3 Results
4.3.1 Accuracy results on dataset 1
Figure 4.4 shows a representative example of lesion segmentation obtained by
MSmetrix-cross, MSmetrix-long and LST-long on a patient from dataset 1.
By comparing against expert delineations, it can be observed that MSmetrix-
long has improved in accuracy over MSmetrix-cross and that LST-long has
missed lesions.
The volumetric correlation of MSmetrix-long and LST-long to the expert
reference segmentation can be visualised in figure 4.5. MSmetrix-long has a
better correlation (r = 0.96) with expert reference segmentation compared to
LST-long (r = 0.88).
Table 4.1 summarises the cross-sectional lesion segmentation performance of
MSmetrix-cross, MSmetrix-long and LST-long on dataset 1 (n = 24) in a
quantitative way. MSmetrix-long has improved over MSmetrix-cross in the
median Dice, F1 score and LFPR. Compared to LST-long, MSmetrix-long has
a higher median Dice, F1 score, LTPR and r value, together with lower LFPR
and absolute lesion volume difference.
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Figure 4.5: Scatter plot of total lesion volume (ml) for reference expert segmentation versus
(a) MSmetrix-long and (b) LST-long.
Table 4.1: Quantitative metrics (voxel-by-voxel, lesion and volumetric level) for measuring
the cross-sectional accuracy of the automatic methods MSmetrix-long, MSmetrix-cross and
LST-long with respect to expert segmentations on dataset 1 (n = 24).
Automatic method Dice F1 score LTPR LFPR Absolute volume difference (ml) r value
MSmetrix-long 0.63 (0.49 - 0.68) 0.61 (0.54 - 0.63) 0.50 (0.43 - 0.59) 0.25 (0.20 - 0.37) 2.09 (1.77 - 3.18) 0.96
MSmetrix-cross 0.60 (0.46 - 0.66)∗∗ 0.56 (0.52 - 0.61)∗ 0.57 (0.52 - 0.65)∗∗ 0.48 (0.36 - 0.55)∗∗ 1.48 (0.81 - 2.59) 0.95
LST-long 0.60 (0.47 - 0.65)∗ 0.48 (0.37 - 0.53)∗∗ 0.42 (0.30 - 0.52)∗ 0.40 (0.30 - 0.47) 2.66 (1.52 - 4.84)∗ 0.88
Except r value, all metrics are reported in median (first quartile - third quartile).
LTPR=lesion-wise true positive rate, LFPR=lesion-wise false positive rate, r value=Pearson correlation coefficient.
* Values significantly different from MSmetrix-long (paired t-test with p < 0.05 significance level).
** Values significantly different from MSmetrix-long (paired t-test with p < 0.01 significance level).
Table 4.2 summarises the lesion-wise change accuracy performance of MSmetrix-
cross, MSmetrix-long and LST-long on dataset 1 in a quantitative way. In
case of new lesions, MSmetrix-long has improved over MSmetrix-cross in the
median F1 score and LFPR. Compared to LST-long, MSmetrix-long has a
higher median F1 score and LTPR. In case of enlarging lesions, MSmetrix-long
has improved over MSmetrix-cross in the median LFPR, with marginally better
F1 score. Compared to LST-long, MSmetrix-long has a higher median F1 score,
LTPR and LFPR. When new and enlarging lesions are combined, MSmetrix-
long has better correlation (r = 0.77) with the expert segmentations compared to
MSmetrix-cross (r = 0.63) and LST-long (r = 0.53). In case of absolute lesion-
wise change difference, MSmetrix-long has marginally better performance
over MSmetrix-cross and LST-long, however, with better correlation with the
lesion-wise change difference of the expert segmentations (r = 0.84) compared
to MSmetrix-cross (r = 0.65) and LST-long (r = 0.72).
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Table 4.2: Lesion-wise quantitative metrics for measuring the lesion change accuracy of the
automatic methods MSmetrix-long, MSmetrix-cross and LST-long with respect to expert
lesion segmentations changes on dataset 1.
New lesions Enlarging lesions New & enlarginglesions
F1 score LTPR LFPR F1 score LTPR LFPR r value
MSmetrix-long 0.42 (0 - 0.55) 0.33 (0 - 0.60) 0 (0 - 0.38) 0.69 (0.56 - 0.81) 0.62 (0.53 - 0.69) 0.16 (0 - 0.51) 0.77
MSmetrix-cross 0.20 (0.0 - 0.62) 0.33 (0 - 0.52) 0.50 (0.31 - 0.75) 0.68 (0.58 - 0.80) 0.59 (0.53 - 0.69) 0.24 (0.15 - 0.43) 0.63
LST-long 0 (0 - 0.43) 0 (0 - 0.29) 0 (0 - 0) 0.60 (0.51 - 0.69) 0.50 (0.35 - 0.60) 0.33 (0.15 - 0.51) 0.53
Absolute lesion-wise change difference
r value
MSmetrix-long 1 (1 - 3.5) 0.84
MSmetrix-cross 1.5 (1 - 3.75) 0.65
LST-long 2 (1 - 3.5) 0.72
Except r value, all metrics are reported in median (first quartile - third quartile).
LTPR=lesion-wise true positive rate, LFPR=lesion-wise false positive rate, r value=Pearson correlation coefficient.
Here, the t-test is not performed, as the sample size is small (n = 12).
Table 4.3: The Dice score, the number (Nr.) of new lesions and the absolute volume
difference (Abs. vol. diff.) between both time points for measuring the accuracy of the
automatic methods MSmetrix-long, MSmetrix-cross and LST-long on dataset 2.
Dice Nr. of new les Abs. vol. diff. (ml)
MSmetrix-long 0.89 (0.85 - 0.91) 0 (0 - 1) 0.11 (0.03 - 0.32)
MSmetrix-cross 0.69 (0.56 - 0.73)∗∗ 3.5 (1 - 5)∗∗ 0.3 (0.17 - 0.54)∗
LST-long 1 (1 - 1)∗∗ 0 (0 - 0)∗∗ 0 ( 0 - 0.01)∗∗
All metrics are reported in median (first quartile - third quartile).
* Values significantly different from MSmetrix-long (paired t-test with p < 0.05 significance level).
** Values significantly different from MSmetrix-long (paired t-test with p < 0.01 significance level).
4.3.2 Reproducibility results on dataset 2
Figure 4.6 shows an example of lesion segmentation obtained by MSmetrix-
cross, MSmetrix-long and LST-long on a patient from dataset 2 (n = 60).
Both MSmetrix-long and LST-long are more consistent in lesion segmentation
compared to MSmetrix-cross. Compared to LST-long, MSmetrix-long also
shows better reproducibility in segmenting small lesions. Quantitatively, LST-
long has the best median Dice with zero error in detecting new lesions and
absolute volume difference between both time points. MSmetrix-long has
improved in the median Dice, with median error in detecting new lesions
and absolute volume difference over MSmetrix-cross (see Table 4.3). The
reproducibility of LST-long is highest because it segments the most certain
hyper-intense lesions in both time points at the expense of missing substantial
amount of less hyper-intense lesions as shown in figure 4.6.
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Figure 4.6: Bias corrected FLAIR image (a) followed by super-imposed lesion segmentation
from: (b) MSmetrix-cross, (c) MSmetrix-long, and (d) LST-long. The first row corresponds
to the lesion segmentation of time point 1 and the second row corresponds to the lesion
segmentation of time point 2. Cyan arrows show some false positives in MSmetrix-cross,
which are absent in MSmetrix-long. Yellow arrows specify places where MSmetrix-long has
consistently segmented some small lesions and red arrows indicate regions where LST-long
misses some potential lesions.
4.4 Discussion and conclusions
Accurate and consistent lesion segmentation is very important in monitoring
the MS disease progression. As manual lesion segmentation is time consuming
and suffers from inter- and intra-rater variability, automated methods have the
advantage of being fast and consistent. The vast majority of automatic methods
are cross-sectional in nature and the average accuracy (Dice) of these methods is
sufficiently high, however, these cross-sectional methods seldom report results on
the lesion evolution accuracy and this hinders a fair comparison of our method
against them. Moreover, another factor to consider is whether the segmentation
method is supervised or unsupervised. We compare our unsupervised method
with other unsupervised methods only because supervised methods often require
a representative training dataset, including expert segmentation, in order to
build a model that can be used on new patients for lesion segmentation. This
training dataset is very difficult to build because MS lesions have all possible
shapes, intensities and are heterogeneously distributed in the WM. Moreover,
the new image to be segmented should be well represented in the training
dataset which is not always possible. Two well known publicly available
unsupervised MS lesion segmentation tools are Lesion-TOADS [146] and LST.
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We choose LST because of two reasons: (1) in chapter 2, we have shown
that our cross-sectional method (MSmetrix-cross) had a better performance
compared to Lesion-TOADS in terms of accuracy and reproducibility. Since
in this chapter we also report results from our cross-sectional method, we
decided that the comparison with Lesion-TOADS is not required, (2) only LST
tool has a longitudinal MS lesion segmentation pipeline. Thus it is logical to
compare MSmetrix-long with LST-long as both methods are unsupervised and
longitudinal in nature.
In this chapter, MSmetrix-long pipeline combines both spatial and temporal
relationships of lesions for accurate and consistent lesion segmentation. The
spatial relationship is based on Markov Random Field and is incorporated
in MSmetrix-cross. The temporal relationship is modelled in a joint
lesion segmentation, which uses difference image and cross-sectional lesion
segmentations of two time points. The difference image models the growth
and shrinkage of lesions and thus helps in recovering those lesions that are
missed by the cross-sectional lesion segmentation. In addition, if a lesion is
present in both time points but has been segmented in only one of the time
point, then the joint lesion segmentation facilitates the recovery of that lesion
at the other time point. Moreover, brain atrophy has also minimal impact on
the performance of MSmetrix-long because (1) atrophy is generally small and
global in nature (2) it occurs near the CSF boundary and these transitions
i.e., (CSF → GM and CSF → WM) are excluded in the difference image
GMM model, (3) we tested global non-rigid registration in addition to affine
registration i.e., non-rigid registration only on a coarse level, to accommodate
for the atrophy and we found out that it has a minimal, but potentially negative
impact on the final lesion segmentation. Therefore, to gain computational
efficiency we excluded this global non-rigid registration from MSmetrix-long
pipeline. Furthermore, we made a choice of using two time points instead of
multiple time points for lesion segmentation as it is unclear whether clinical
users would benefit from a long-term longitudinal analysis method. Indeed,
incorporating multiple time points at once would be more consistent and more
robust as more information is available compared to two time points. On the
other hand, longitudinal consistency over multiple time points might perhaps
also influence the accuracy of individual lesion segmentation. Change in the
imaging protocols in a longitudinal follow-up also makes multiple time point
analysis more difficult. Moreover, radiological reporting guidelines recommend
comparison of current MRI against previous time point [169]. Lesion changes
between successive time points (e.g., new lesions) are relevant information for
clinicians, as it is essential to capture disease evolution, instead of disease history.
Thus, a two-time point approach can always be applied between successive visits,
without the need to incorporate a longer history into the analysis. Once the
method is feasible for two time points, it can be applied in a multi-time point
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fashion. We have actually performed a study on a large retrospective dataset
from a clinical trial (unfortunately, we are not allowed to publish the results
in this thesis), where patients were annually monitored for a longer period of
time. When grouping time points in pairs, e.g., (TP1, TP2) and (TP2, TP3),
we observed a high consistency in total lesion volume at the middle time point
(TP2), without having to use more than 2 time points simultaneously.
Among the methods proposed in the literature for longitudinal lesion
segmentation, our approach has some similarities to [48] and [2], which are also
based on EM frameworks. In contrast with [48], our method is unsupervised and
can segment new, enlarging, disappearing and shrinking lesions. As opposed
to [2], our joint EM model takes cross-sectional lesion segmentation as prior
information on the lesion class in both time points and processes each time
point in its own space to avoid bias in the lesion segmentation.
In order to evaluate the effect of the pruning step, we also calculated the
cross-sectional accuracy (Dice, LTPR and LFPR) of MSmetrix-long after the
joint lesion segmentation step. The Dice, LTPR and LFPR (reported in median
(first quartile - third quartile)) after the joint lesion segmentation step are 0.60
(0.45 - 0.65 ), 0.64 (0.54 - 0.69) and 0.81 (0.72 - 0.87) respectively. Comparing
these results with the the voxel-by-voxel accuracy of MSmetrix-long after the
pruning step (see table 4.1), we observe that the pruning step increases the
overall Dice score by decreasing the false positive rate at the expense of a
decrease in true positive rate.
In order to investigate the cause of low lesion-wise true positive rate for cross-
sectional accuracy of MSmetrix-long compared to MSmetrix-cross (see table
4.1), we calculated the average lesion-wise true positive rate for small (0.003 ml -
0.01 ml), medium (0.01 ml - 0.05 ml) and large ( > 0.05 ml) lesion volumes. The
average lesion-wise true positive rate for MSmetrix-long and MSmetrix-cross
for small lesions is 0.13 and 0.27 respectively, followed by medium lesions 0.30
and 0.37 and large lesions 0.75 and 0.81. It can be seen that MSmetrix-long
misses more small and medium size lesions. The primary cause of missing
these lesions is that they are either iso-intense with grey matter intensities
(thus missed by intensity threshold mask used in the pruning step) or they are
removed by the binary false positive mask (used in the pruning step). However,
it is important to note that both intensity threshold mask and binary false
positive mask play a key role in reducing the false positives as described in the
previous paragraph.
One important aspect of MSmetrix-long is that its performance is dependent
on the cross-sectional lesion segmentation. This suggests that if MSmetrix-
cross has either consistently missed a lesion, or segmented a non-lesion at
both time points, then it will be either missed or retained by MSmetrix-long,
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respectively. As presented in the result section, MSmetrix-long is more accurate
and reproducible than MSmetrix-cross. The increase in cross-sectional accuracy
(Dice, F1 score) and lesion change accuracy for new lesions (F1 score) is due
to the reduction in lesion-wise false positive rate using the lesion segmentation
information from the other time point. For enlarging lesions, a marginal increase
in the median F1 score is observed for MSmetrix-long due to larger differences
in the lesion segmentation boundary between the expert and MSmetrix-long.
MSmetrix-long has also slightly better absolute lesion-wise change difference
compared to MSmetrix-cross primarily due to a reduction in lesion-wise false
positive rate. A modest decrease in the absolute volume difference is due
to the under-segmentation of lesions by MSmetrix-long (figure 4.5) and the
elimination of a few lesions that are close to the cerebral cortex. Interestingly,
a substantial lesion-wise false positive rate in MSmetrix-cross suggests that
the false lesions compensate towards missed lesions volume resulting in a
lower absolute volume difference compared to MSmetrix-long. The significant
improvement in reproducibility (Dice, number of new lesions and absolute
volume difference) of MSmetrix-long could also be explained by the benefit of
using the lesion segmentation of the other time point.
In comparison to LST-long, MSmetrix-long is more accurate (Dice, F1 score)
and slightly less reproducible. Cross-sectionally, LST-long has higher absolute
volume difference and lesion-wise false positive rate; lower lesion-wise true
positive rate and F1 score on dataset 1. The high absolute volume difference
of LST-long could be explained by the over-segmentation of lesion boundaries.
A high lesion-wise false positive rate of LST-long could be explained by the
segmentation of FLAIR artefacts or cortical foldings as lesions. For the lesion
change accuracy, MSmetrix-long has superior performance for all measures
compared to LST-long. This could be explained by the fact that LST-long
segments the most hyper-intense lesions and is thus very consistent (see table-
4.3), but misses many small less hyper-intense lesions (figure 4.4, figure 4.6).
In conclusion, we have presented MSmetrix-long: an iterative two time point
white matter lesion segmentation method based on a joint EM framework using
two time points. The proposed method is unsupervised and can segment new,
enlarging, disappearing, shrinking and static lesions. We first analyse both time
points separately followed by a joint lesion segmentation, which models the
lesion evolution as a Gaussian mixture model. The accuracy and reproducibility
of MSmetrix-long is compared with MSmetrix-cross and the publicly available
lesion segmentation tool LST-long on two datasets that are representative
for clinically feasible acquisition protocols. MSmetrix-long has outperformed
MSmetrix-cross. Compared to LST-long, MSmetrix-long has better accuracy
and similar reproducibility.
Chapter 5
Clinical relevance of new
and enlarging lesion volume
in RRMS
Abstract
MRI has become an integral part in monitoring multiple sclerosis disease.
Several MRI markers have been explored in this direction, e.g., total lesion
load and new and enlarging lesions count. However, the volume of the new
and enlarging lesions (NEL) as an MRI marker has never been explored for
its possible relationship with the most widely used clinical marker: Expanded
Disability Status Scale (EDSS) score. In this study, we explored the association
of these two markers on RRMS patients. NEL volume is computed using
MSmetrix-long, where only the enlarged part of the enlarging lesion is used for
the volume computation together with the new lesion volume. The relationship
between NEL volume and EDSS score is explored both at group level and
on an individual level using a multi-centre dataset consisting of images from
three centres. NEL volume correlates better with EDSS score’s evolution at
individual level than at a group level, where a low correlation is observed.
Nevertheless, this study shows the applicability of our method on multi-centre
datasets without re-tuning or re-training, which makes it useful for the clinical
use.
This chapter has been accepted for poster presentation at the conference: The consortium of Multiple Sclerosis
Centres (2017), Jain, S., Sima, D.M., Van Vlierberghe, E., Dubois, B., Dupont, P., Kocevar, G., Durand-Dubief, F.,
Sappey-Marinier, D., Wang, C., Barnett, M.H., Van Huffel, S., Maes, F. and Smeets, D. Clinical relevance of new
and enlarging lesion volume in Relapsing Remitting Multiple Sclerosis: A multi-centre study.
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5.1 Introduction
MRI of the brain has shown its effectiveness in MS disease in various dimensions
such as disease diagnosis [119, 148], monitoring, prognosis [11, 114, 56] and
testing of drug efficacy [105, 157]. Towards this end, several MRI markers
have been explored such as total lesion volume [51, 53, 22], T1 hypointense
lesions (black holes) [10, 110, 106, 68], whole brain atrophy [120, 55, 147, 81]
and new lesions (based on contrast enhanced T1-weighted image and/or T2-
weighted/FLAIR image) count and volume [33, 44, 3]. Total lesion volume
provides information on the cumulative disease burden. Black holes are seen as a
marker of neuronal destruction and axonal loss, and have shown correlation with
EDSS score [178]. Whole brain atrophy provides insights on the brain tissue loss
and is associated with the long term cognitive impairment, fatigue and increase
in the EDSS score [39, 156]. New lesions based on the T2 -eighted/FLAIR image
suggest an inflammatory reaction that has developed between two MRI scans
and provide information on the disease activity and disease progression. New
lesions based on the contrast enhanced T1-weighted image are associated with
the active inflammation in the brain due to the disruption of the blood-brain
barrier and have shown to be more correlated than T2/FLAIR lesions with the
number of relapses (attack when MS symptoms flare up) that a patient has
experienced [3, 44]. It is important to mention that the correlation of MRI
markers with clinical markers is not very strong [157, 155, 95], as MRI is more
sensitive in detecting disease activity earlier in time [119].
Enlarging lesions as a potential MRI marker have also been investigated for
monitoring the disease activity and testing of drug efficacy [3, 155, 133]. There
are not many studies that include enlarging lesions. A possible reason could
be that these studies generally have an expert panel, which is required to
examine every enlarging lesion segmentation in longitudinal scans, and this is
very time consuming. Automatic MS lesion segmentation tools can be used
to find enlarging lesions; however, counting the enlarging lesions using these
softwares is often debatable.
The aim of this study is to investigate the role of new and enlarging lesion volume
in monitoring the RRMS disease activity using MSmetrix-long, as described
in chapter 4. We choose this because to the best of our knowledge, volume of
the new and enlarging lesions has never been explored for its association with
the EDSS score in RRMS patients. In particular, we explore the relationship
between the new and enlarging lesion volume and change in the EDSS score,
both on a group level and on an individual patient level using multi-centre
datasets.
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5.2 Methods
The new and enlarging lesion volume between two consecutive time points is
computed using the lesion segmentations obtained from MSmetrix-long. A
new lesion is defined as the lesion present only at the second time point and an
enlarging lesion is defined as the lesion whose overall volume is increased by
more than 5% compared to the previous time point. In this study we used the
volume of the enlarged part of the enlarging lesion, which defines the increment
in the lesion volume.
5.2.1 Data
Dataset 1 contains scans from 30 RRMS patients acquired on a SIEMENS
1.5T scanner (Sonata), each scanned at least three times at an interval of
approximately 6 months or 12 months. Each time point contained two sequences:
3D T1-weighted and 2D FLAIR, and their details are described in table 5.1.
For this dataset the EDSS score was available at all MRI examination dates.
This study was carried out in accordance with the recommendations of the
French national agency for medicine and health products safety (ANSM) and
was approved by the local ethical committee (CPP Sud-Est IV). All subjects
gave written informed consent.
Dataset 2 contains scans from 20 RRMS patients acquired on a GE 3T scanner
(Discovery MR750), each scanned twice at an interval of approximately one
year. Each time point contained two 3D sequences: T1-weighted and FLAIR,
and their details are described in table 5.1. For this dataset the EDSS score was
available at both MRI examination dates along with one in the future time (no
MRI scan for the future time). This study was reviewed and conducted within
the guidelines set out in the National Statement on Ethical Conduct in Human
Research (2007) in Australia, and approved by University of Sydney Human
Research Ethics Committee. All subjects gave written informed consent.
Dataset 3 contains scans from 35 RRMS patients acquired on a Philips 3T
scanner, each scanned at least twice at a variable time interval ranging from
approximately 4 to 12 months. Each time point contained two 3D sequences:
T1-weighted and FLAIR, and their details are described in table 5.1. For this
dataset the EDSS scores were not always available nearby the MRI examination
date, therefore we used only those MRI scans where at least two EDSS scores
were available having a maximum delay of ± 6 months from their closest MRI
examination date. 4 out of 35 subjects had matching EDSS scores and MRI
scans available and only these 4 subjects were used in this study. This study
was carried out in accordance with the recommendations of the Belgian and
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Table 5.1: Sequences description for all three datasets.
Sequence TR (ms) TE (ms) TI (ms) FOV (mm2) Voxel size (mm3) No. of slices
Dataset 1
3D T1-weighted MPRAGE 1970 3.93 1100 256 × 256 1 × 1 × 1 176
2D FLAIR TSE 8000 105 2200 180 × 240 0.94 × 0.94 × 3 46
Dataset 2
3D T1-weighted IR-FSPGR 7.2 450 2.8 230 × 230 0.9 × 0.9 × 0.9 188
3D FLAIR CUBE 8000 165 2179 240 × 240 0.60 × 0.47 × 0.47 280
Dataset 3
3D T1-weighted MPRAGE 9.64 4.6 NA 250 × 250 0.98 × 0.98 × 1.2 140
3D FLAIR SENSE 4800 360.2 1650 250 × 250 1 × 1 × 0.55 321
NA = Not available.
Dutch legislation and was approved by the UZ Leuven ethical committee. All
subjects gave written informed consent.
5.2.2 Study design
We analyse the relationship between new and enlarging lesion volume and EDSS
score both at group level and individual level. At group level, the correlation
between EDSS change (difference between the last and the first EDSS score)
and new and enlarging lesion volume is investigated using Pearson correlation
coefficient (r value). Since dataset 3 has only four subjects that had matching
EDSS scores and MRI scans, no separate group analysis was performed for
this dataset. At individual level, for every subject, EDSS scores and new and
enlarging lesion volumes are plotted against their corresponding examination
dates as time points. The aim of the individual study is to analyse whether the
evolution of new and enlarging lesion volume can correlate with the evolution of
the EDSS score. Since dataset 2 has only two time points, it is excluded from
the individual study.
5.3 Results
5.3.1 Group analysis
Figure 5.1 shows the scatter plots between EDSS change and new and enlarging
lesion volume for dataset 1, dataset 2 and all datasets combined. Although
the correlation is low, it increases when the values from all three datasets are
included simultaneously in the analysis.
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Figure 5.1: Scatter plots between EDSS change and new and enlarging lesion volume for
dataset 1 (left), dataset 2 (middle) and all datasets combined (right).
5.3.2 Individual analysis
Dataset 1
Figures 5.2, 5.3 and 5.4, show the evolution of EDSS score and new and enlarging
lesion volume for each subject over time for dataset 1. From the figures 5.2
and 5.3 (n = 21) it can be seen that with an increase in the new and enlarging
lesion volume, the EDSS score is increased either at the current time point or in
the future time point. With a decrease in the new and enlarging lesion volume,
the EDSS score is either decreased or it remains nearly the same. Lastly, when
the new and enlarging lesion volume equally increases and decreases over time
(random behaviour), the EDSS score fairly remains constant. However, the
remaining subjects (n = 9) in the figure 5.4 exemplify the cases where this trend
is absent.
Dataset 3
Figure 5.5 shows the evolution of EDSS score and new and enlarging lesion
volume for each subject over time for dataset 3. Three out of four subjects
show the same trend as observed in dataset 1 (with an increase in the new and
enlarging lesion volume, the EDSS score is increased either at the current time
point or in the future. With a decrease in the new and enlarging lesion volume,
the EDSS score is either decreased or it remains nearly the same). An opposite
trend is observed for the subject 4.
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(a) Subject 1 (b) Subject 2 (c) Subject 3
(d) Subject 4 (e) Subject 5 (f) Subject 6
(g) Subject 7 (h) Subject 8 (i) Subject 9
(j) Subject 10 (k) Subject 11 (l) Subject 12
Figure 5.2: Examination time points versus EDSS score (in blue) and new and enlarging
lesion volume (in red) for dataset 1.
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(a) Subject 13 (b) Subject 14 (c) Subject 15
(d) Subject 16 (e) Subject 17 (f) Subject 18
(g) Subject 19 (h) Subject 20 (i) Subject 21
Figure 5.3: Examination time points versus EDSS scores (in blue) and new and enlarging
lesion volumes (in red) for dataset 1.
5.4 Discussion and conclusions
Accurate and reliable quantification of MRI derived measures such as new and
enlarging lesion volume is very important. Majority of the literature studies
quantify these measures using either expert segmentations or using automated
segmentation tools. While the former is most accurate, it often suffers from intra
and inter rater variability, and has low reproducibility of lesion segmentations on
the follow-up time points. Compared to expert lesion segmentations, automated
lesion segmentation tools are generally more reproducible but less accurate.
Additionally, large majority of MS lesion segmentation tools are cross-sectional
(based on a single time point) in nature, which affects their reproducibility.
Automated longitudinal MS lesion segmentation tools address this problem
and optimise for accuracy and reproducibility simultaneously using using lesion
segmentation information from two or more time points. In this study we have
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(a) Subject 22 (b) Subject 23 (c) Subject 24
(d) Subject 25 (e) Subject 26 (f) Subject 27
(g) Subject 28 (h) Subject 29 (i) Subject 30
Figure 5.4: Examination time points versus EDSS scores (in blue) and new and enlarging
lesion volumes (in red) for dataset 1.
chosen a two time points MS lesion segmentation tool (MSmetrix-long) that
has shown to have a good balance between accuracy and reproducibility (see
chapter 4).
Quantification of new and enlarging lesion volume from the obtained lesion
segmentations is also challenging. The two main problems are: (a) lesion
boundary error between two time points causing a lesion to be classified as an
enlarging lesion or not (b) choice of enlarging lesions i.e., considering lesions that
are only enlarged (i.e., no shrinking) or also consider lesions that have enlarged
at one location and shrunk at another location. Since we use MSmetrix-long,
which is more reproducible, the severity of the first problem is reduced. For
the second problem, we assumed that the enlarging part of the enlarging lesion
(irrespective of whether it has shrunk or not) is more important for disease
monitoring since it indicates active inflammation.
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(a) Subject 1 (b) Subject 2
(c) Subject 3 (d) Subject 4
Figure 5.5: Examination time points versus EDSS scores (in blue diamond) and new and
enlarging lesion volumes (in red circle) for dataset 3.
Another challenge in our study was the availability of a dataset that satisfies our
requirements. It includes: (1) availability of EDSS score near MRI examination
date (2) periodic follow up of patients (3) no therapy change. As the EDSS
score is the patient’s disability state at a given time point, it is necessary that
the MRI scan was taken nearby e.g., ± 6 months. Periodic follow-up of patients
helps in analysing the lesion evolution pattern and investigating its relationship
with EDSS evolution over time. In this study, the increase in new and enlarging
lesion volume seems to show an increase in the EDSS score in a near future.
However, as the number of subjects used in this study is low, a larger population
study is needed to confirm this observation. Lastly, it is also important that
the patient’ therapy is not changed over time as it will influence both MRI
and clinical measurements. All these requirements are very difficult to meet in
clinical practice and thus pose a big challenge.
In this study we explored the relationship between EDSS score and new and
enlarging lesion volume using three different multi-centre datasets. The new and
enlarging lesion volume was computed with MSmetrix-long and the analysis
was performed both on a group and on an individual level. On a group level,
a weak correlation between EDSS score and new and enlarging lesion volume
could be explained by the scientific evidence that MRI is a more sensitive disease
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activity marker than the EDSS score [119]. We also observed a similar trend
in our individual study where the change in new and enlarging lesion volume
happened before the actual change in the EDSS score. Note that the new and
enlarging lesion volume may also relate to other symptoms, such as cognitive
scores (which are not captured in the EDSS score), and will be explored in the
future.
In conclusion, this study showed interesting trends in the data. In majority
of the cases, NEL volume correlates better with EDSS score’s evolution at
individual level, although at a group level, the correlation between these two
variables is low. An extensive further validation is required to explore other
confounding factors. Nevertheless, this study shows the applicability of our
method on multi-centre datasets without re-tuning or re-training, which makes
it useful for the clinical use.
Chapter 6
Conclusions and future
work
6.1 Main contributions
Accurate and consistent MS lesions segmentation has been demonstrated to be
a valuable step in the clinical routine evaluation of MS patients. Enhancing the
spatial resolution of quantified MR spectroscopic maps in MS patients can help
for better characterisation of small lesions.
6.1.1 Methods
In this work, the following scientific contributions were made:
• MSmetrix-cross: An iterative, EM based method that segments a MR
image of an MS brain into GM, WM, CSF and lesions. A GMM model is
used to model tissue class intensities of GM, WM and CSF and lesions
are detected as an outlier to this GMM model.
• PBSR: This super-resolution technique uses MSmetrix-cross outputs as
prior knowledge to regularise the reconstruction process. The algorithm
iteratively estimates the expected metabolite value in every high-resolution
MRSI voxel using segmentations and tissue intensities information; and
then corrects these expected metabolite values using the input low
resolution MRSI map.
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• MSmetrix-long: An iterative, joint EM based method for two time points
lesion segmentation. The method uses MSmetrix-cross outputs of the
two time points as prior knowledge along with the FLAIR based difference
image to improve the lesion segmentation at both time points.
6.1.2 Results and discussion
The results presented in this thesis addressed two main problems: MS lesion
segmentation and MRSI super-resolution.
MS lesion segmentation
MSmetrix-cross
We showed that MSmetrix-cross has good accuracy and reproducibility with
some systematic undersegmentation and it misses small lesions that are less
than five voxels. Comparing with state-of-the-art methods, the accuracy of
MSmetrix-cross outperformed two lesion segmentation tools: LST and Lesion-
TOADS. Regarding the reproducibility, MSmetrix-cross and LST had similar
performance and both methods outperformed Lesion-TOADS.
MSmetrix-long
We showed that MSmetrix-long consistently segments lesions at two time
points by decreasing the lesion-wise false positive rate with slight reduction
in lesion-wise true positive rate. The method’s performance is dependent on
the MSmetrix-cross and thus requires good cross-sectional lesion segmentation.
Comparing with state-of-the-art methods, the accuracy and reproducibility
of MSmetrix-long outperformed MSmetrix-cross. In comparison to LST-
long, MSmetrix-long is more accurate and slightly less reproducible (LST-long
segments the most hyper-intense lesions). Moreover, initial results showed that
new and enlarging lesion volume may correlate with the EDSS score’s evolution
for individual patients. However, a low correlation between these two variables
at group level requires an extensive validation to explore other confounding
factors.
MRSI super-resolution
We showed that the patch-based super-resolution method preserves tissue
contrast and structural information compared to conventional interpolation
methods, and matches well with the trend of acquired high-resolution MRSI. The
method cannot recover small scale features that were not sufficiently expressed
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in the low resolution MRS image and is applicable only if the difference between
the image resolution of MRI and MRSI images is less than a scale factor of four.
6.2 Future perspectives
We believe that both patch based super-resolution and two time points lesion
segmentation methods can be further improved, and we now mention some
possibilities in that direction.
Patch-based super-resolution
In chapter 3, the PBSR method uses a parameter α that controls the contribution
of MRI and MRSI images in the super-resolution process, and was derived
using lesion segmentation of FLAIR image. As the actual damage is beyond
what is seen on the FLAIR image, MRSI should have more contribution in
the vicinity of the lesion. However, the important question is, to what extent?
For this, advanced imaging methods such as magnetic transfer imaging and
diffusion tensor imaging that are more sensitive than conventional MRI and have
better resolution than MRSI could be used to derive this information. However,
care should be taken that the resulting high-resolution image is plausible and
does not create features that are not seen in MRSI. Also, the benefit of using
multi-scale resolution approach could not be tested on the real images as the
data was already acquired and thus the resolution was fixed. With the use of a
7T scanner and parallel imaging techniques, we hope to acquire MRSI datasets
from more patients at 2×2 mm2, 3×3 mm2 and 4×4 mm2 in-plane resolution
and thus test the benefit of the multi-scale approach and further validate our
method.
In the present study, only NAA and myo-Ins metabolites are used as they
are one of the most common metabolites of interest in MS. Conceptually, the
super-resolution method developed could easily be applied to upsample any
metabolite of interest. Simultaneous multiple metabolites upsampling is also
very interesting to investigate, as the information from each metabolite aids in
the reconstruction of other metabolites.
Two time points lesion segmentation
In this thesis, two time points lesion segmentation currently segments MS
lesions of the two time points. However, temporal consistency of the other tissue
classes can also be incorporated in the same framework using a temporal Markov
Random Field. One of the important challenges in developing this would be
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computation time, which is a crucial factor in real time. Using the graphical
processing unit (GPU) can alleviate this problem to a great extent. Additionally,
histogram normalisation is based on cumulative histogram matching, which
may be sensitive to lesion changes as these would show up in the histogram,
e.g., normalising an image with low lesion load with an image with significant
lesion load may result in histograms that are representing two scenarios. This
problem could be addressed by doing tissue based intensity normalisation such as
proposed in [82], where the joint histograms (e.g., T1-weighted and FLAIR) of
the two time points are non-rigidly registered to find the intensity transformation
function. Finally, we observed that the lesion-wise true positive rate is decreased
from our single time point to two time points lesion segmentation methods. It
would be a great challenge to improve the lesion-wise true positive rate without
compromising on reproducibility. ‘Deep learning’ algorithms have become very
popular nowadays and may address this problem. Deep learning methods are
training based methods that can model a high level of abstraction in the data
which is not obvious to the human eye. Using the MSmetrix-cross pipeline,
the required training data may be generated.
In chapter 5 we explored the relationship of new and enlarging lesions volume
with the EDSS score. EDSS score does not capture all aspects of MS such
as cognitive decline or disease progression, therefore, scores such as Multiple
Sclerosis Functional Composite (MSFC) [36] and Multiple Sclerosis Severity
Score (MSSS) [138] would be explored for their association with MRI biomarkers.
To investigate and validate potential MRI biomarker/s, a large retrospective
study is desirable and should be conducted with clinical biomarkers information
taken periodically. Also, this study would help in making a lesion ageing
population graph that can serve as a template for disease progression and
evaluation of drug efficacy. Finally, according to the revised McDonald criteria,
infratentorial, periventricular or juxtacortical brain regions are considered
of high importance for disease diagnosis [119]. Therefore, regional lesion
classification and association between lesion location and clinical symptoms is
also an interesting future perspective.
From this research we conclude that the developed multiple sclerosis lesion
segmentation methods, through their robustness and automation, could bring
an added value to the clinical routine evaluation of multiple sclerosis patients.
Also, the patch-based high-resolution MR spectroscopic images, through its
tissue contrast conservation, can offer better lesion characterisation.
Appendix A
Accuracy and
reproducibility of LST and
Lesion-TOADS
Overview
This appendix provides additional information and supporting figures regarding
the accuracy and reproducibility for publicly available lesion segmentation tools
LST and Lesion-TOADS as described in chapter 2.
A.1 Accuracy results on dataset 1
Best case for LST
Figure A.1 shows the best case for LST (Dice: 0.80, sensitivity: 0.80 and
precision: 0.79). This case has Dice: 0.82, sensitivity: 0.76, precision: 0.90 for
MSmetrix-cross and Dice: 0.70, sensitivity: 0.54, precision: 0.98 for Lesion-
TOADS. The higher sensitivity of LST compared to the other two methods is
caused by the detection and segmentation of subtle lesions (marked by a pink
arrow head); however, the lower precision of LST suggests that it introduced
false lesions and it overestimated the lesion boundary (see region marked by
cyan arrow heads). MSmetrix-cross has higher Dice similarity index than LST
due to lower number of false positive lesion voxels.
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Figure A.1: Original FLAIR image (a) followed by bias corrected FLAIR image and super-
imposed lesion segmentation from: (b) expert segmentation, (c) MSmetrix-cross, (d) LST,
(e) Lesion-TOADS. Cyan arrow heads show false positive lesions and overestimation of the
lesion boundaries in LST. Pink arrow head show lesions picked by LST but not by the other
methods except partially one in Lesion-TOADS.
Figure A.2: Original FLAIR image (a) followed by bias corrected FLAIR image and super-
imposed lesion segmentation from: (b) expert segmentation, (c) MSmetrix-cross, (d) LST,
(e) Lesion-TOADS. Cyan arrow heads show false positive lesions in Lesion-TOADS. Purple
arrow heads show missed subtle lesions and underestimation of lesion boundary.
Worst case for LST and Lesion-TOADS
Figure A.2 shows the worst case for LST (Dice: 0.31, sensitivity: 0.21 and
precision: 0.58), which is also the worst case for Lesion-TOADS (Dice: 0.44,
sensitivity: 0.38 and precision: 0.52). Here, MSmetrix-cross has a better Dice
similarity index, sensitivity and precision compared to the other two methods
(Dice: 0.52, sensitivity: 0.40, precision: 0.76). The low sensitivity and precision
of LST are due to the fact that it did not find the big lesion, indicated by the
purple arrow head in (d). On the other hand, for MSmetrix-cross and Lesion-
TOADS, low sensitivity is due to missing subtle lesions and/or underestimation
of lesion boundary (purple arrow head). Lesion-TOADS has a lower precision
compared to MSmetrix-cross because it finds a lot of false positive lesions
(cyan arrow head).
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Figure A.3: Bias corrected FLAIR image (a) and super-imposed lesion segmentation from:
(b) MSmetrix-cross, (c) LST, (d) Lesion-TOADS. The first row corresponds to the lesion
segmentation of scan 1 and the second row corresponds to the lesion segmentation of scan 2.
Cyan arrow heads show missed lesions and difference in the lesion segmentation boundary
between scan 1 and scan 2 for Lesion-TOADS.
A.2 Reproducibility results on dataset 2
Best case for LST
Figure A.3 shows the best case for LST (Dice: 0.84). In this case, MSmetrix-
cross has a similar Dice of 0.83 followed by Lesion-TOADS (Dice: 0.78). A
lower Dice similarity index for Lesion-TOADS is mainly due to the inconsistent
estimation of lesion boundaries (marked by cyan arrow heads) compared to
MSmetrix-cross and LST, which are more consistent in the lesion segmentation
in both scans. However, on the other hand, Lesion-TOADS misses big lesions
(marked by cyan arrow heads) whereas MSmetrix-cross and LST detect them
successfully.
Best case for Lesion-TOADS
Figure A.4 shows the best case for Lesion-TOADS (Dice: 0.82). In this case,
LST and MSmetrix-cross have comparable Dice of 0.79 and 0.77, respectively.
The higher Dice similarity index for Lesion-TOADS compared to MSmetrix-
cross and LST is mainly due to its quite consistent performance in estimation
of lesion boundaries in scan 1 and scan 2 for this case. A lower Dice similarity
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Figure A.4: Bias corrected FLAIR image (a) and super-imposed lesion segmentation from:
(b) MSmetrix-cross, (c) LST, (d) Lesion-TOADS. The first row corresponds to the lesion
segmentation of scan 1 and the second row corresponds to the lesion segmentation of scan 2.
Cyan arrow heads represent false lesion detection for MSmetrix-cross and LST.
index for both MSmetrix-cross and LST accounts for (probably) several false
lesions in either of the scans (marked by cyan arrow heads).
Worst case for LST
Figure A.5 shows the worst case for LST (Dice: 0). In this case, MSmetrix-
cross and Lesion-TOADS have comparable Dice of 0.38 and 0.35, respectively.
Before we explain the results, it is important to mention here that this subject
has very few lesions. A zero Dice similarity index for LST is primarily due to
the fact that it is unable to find any lesions in scan 1, but it finds some lesions in
scan 2. Both MSmetrix-cross and Lesion-TOADS consistently find both true
lesions (pink arrow head) and false lesions (cyan arrow head) across the scans.
However, the lower Dice similarity index for Lesion-TOADS accounts for slightly
more false lesion detection in either of the scans compared to MSmetrix-cross.
Worst case for Lesion-TOADS
Figure A.6 shows the worst case for Lesion-TOADS (Dice: 0.15). In this case,
LST has the best performance (Dice: 0.63) followed by MSmetrix-cross (Dice:
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Figure A.5: Bias corrected FLAIR image (a) and super-imposed lesion segmentation from:
(b) MSmetrix-cross, (c) LST, (d) Lesion-TOADS. The first row corresponds to the lesion
segmentation of scan 1 and the second row corresponds to the lesion segmentation of scan 2.
Cyan arrow heads show false lesions detection for MSmetrix-cross and Lesion-TOADS. Pink
arrow heads show subtle lesions that are picked up by MSmetrix-cross and Lesion-TOADS.
Figure A.6: Bias corrected FLAIR image (a) and super-imposed lesion segmentation from:
(b) MSmetrix-cross, (c) LST, (d) Lesion-TOADS. The first row corresponds to the lesion
segmentation of scan 1 and the second row corresponds to the lesion segmentation of scan
2. Cyan ellipses represent the non-overlapping lesions between scan 1 and scan 2 for Lesion-
TOADS, which are probably false positives. Cyan arrow heads show false lesion detection by
MSmetrix-cross and imprecise lesion boundary estimation by LST in both scans.
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0.40). The lower Dice similarity index for Lesion-TOADS is primarily due to
the fact that quite some non-overlapping lesions are found, which are probably
false positives (cyan ellipse). For LST, the higher Dice similarity index is mainly
because it consistently finds lesions across the scans. A low Dice similarity
index for MSmetrix-cross is mainly due to some false lesion detection in either
of the scans (marked by cyan arrow heads). Although the Dice similarity index
is higher for LST compared to MSmetrix-cross, LST is slightly imprecise in
lesion boundary estimation (marked by cyan arrow heads) for this case.
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